77 results on '"Budaj, Andrzej"'
Search Results
2. Platelet reactivity and activated clotting time predict hemorrhagic site complications in patients with chronic coronary syndromes undergoing percutaneous coronary interventions
- Author
-
Ramotowski, Bogumił, Lewandowski, Paweł, Słomski, Tomasz, Maciejewski, Paweł, and Budaj, Andrzej
- Published
- 2024
- Full Text
- View/download PDF
3. Well-palpable pulse over an occluded radial artery: A case series reporting ultrasound outcomes
- Author
-
Lewandowski, Paweł, Zuk, Anna, and Budaj, Andrzej
- Abstract
We report a case series of four patients with radial artery occlusion complicating vascular access who were scheduled for coronary angiography. We describe the challenges in selecting adequate vascular access in patients with a history of coronary angiography and percutaneous coronary intervention, as well as the benefits of using preprocedural ultrasound examination of forearm arteries to detect radial artery occlusion. Our case series suggests that if the anterior interosseous artery provides partial blood supply to the hand as a collateral circulation of the occluded radial artery, the transulnar approach may be an alternative safe option for coronary angiography and percutaneous coronary intervention in this population.
- Published
- 2024
- Full Text
- View/download PDF
4. A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection
- Author
-
Lewandowski, Paweł, Baran, Jakub, Maciejewski, Paweł, and Budaj, Andrzej
- Abstract
Abstract.Background:Iatrogenic pseudoaneurysms (IPA) are treated with ultrasound-guided thrombin injections (UGTI). We describe a novel technique for IPA repair that applies UGTI with thrombin foam (UGTFI). Methods and results:Successful obliteration of 6 IPAs (IPA without a neck, n = 5; with a neck, n = 1) in 6 patients (2 males, aged 68 ± 1 years, 4 females, aged 59 ± 11 years) was performed by using UGTFI. The dose of administered thrombin was 25–75 IU. No microembolization phenomenon and no serious clinical complications were observed. Conclusions:Treatment of IPA with UGTFI may reduce the embolization rate, risk of IPA cavity thrombin leakage, required drug dose. Use of the thrombin foam could be the next step in the development of the UGTI, particularly in the treatment of IPA without a neck.Keywords:Iatrogenic pseudoaneurysms, thrombin, ultrasound-guided thrombin injection, UGTI
- Published
- 2024
- Full Text
- View/download PDF
5. Sex-specific presentation, care, and clinical events in individuals admitted with NSTEMI: the ACVC-EAPCI EORP NSTEMI registry of the European Society of Cardiology
- Author
-
Nadarajah, Ramesh, Ludman, Peter, Laroche, Cécile, Appelman, Yolande, Brugaletta, Salvatore, Budaj, Andrzej, Bueno, Hector, Huber, Kurt, Kunadian, Vijay, Leonardi, Sergio, Lettino, Maddalena, Milasinovic, Dejan, and Gale, Chris P
- Abstract
Graphical AbstractAnalysis of the ACVC-EAPCI EORP NSTEMI registry stratified by sex.
- Published
- 2024
- Full Text
- View/download PDF
6. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
- Author
-
Rao, Sunil V., Kirsch, Bodo, Bhatt, Deepak L., Budaj, Andrzej, Coppolecchia, Rosa, Eikelboom, John, James, Stefan K., Jones, W. Schuyler, Merkely, Bela, Keller, Lars, Hermanides, Renicus S., Campo, Gianluca, Ferreiro, José Luis, Shibasaki, Taro, Mundl, Hardi, Alexander, John H., Hengstenberg, Christian, Steinwender, Clemens, Alber, Hannes, Steringer-Mascherbauer, Regina, Schober, Andreas, Auer, Johann, Roithinger, Franz Xaver, von Lewinski, Dirk, Moertl, Deddo, Huber, Kurt, Coussement, Patrick, Hoffer, Etienne, Beauloye, Christophe, Janssens, Luc, Vranckx, Pascal, De Raedt, Herbert, Vanassche, Thomas, Vrolix, Matthias, Rokyta, Richard, Parenica, Jiri, Pelouch, Radek, Motovska, Zuzanna, Alan, David, Kettner, Jiri, Polasek, Rostislav, Cermak, Ondrej, Sedlon, Pavel, Hanis, Jiri, Novak, Martin, Belohlavek, Jan, Horacek, Thomas, Leggewie, Stefan, Wenzel, Philip, vom Dahl, Juergen, Sievers, Burkhard, Pulz, Jan, Schellong, Sebastian, Clemmensen, Peter, Muller-Hennessen, Matthias, Rassaf, Tienush, Falukozi, Jozsef, Ruzsa, Zoltan, Tomcsanyi, Janos, Csanadi, Zoltan, Herczeg, Bela, Koszegi, Zsolt, Vorobcsuk, Andras, Kiss, Robert, Baranyai, Csaba, Dezsi, Csaba, Merkely, Bela, Lupkovics, Geza, Rossini, Roberta, Scherillo, Marino, Sergio Saba, Pier, Calogero Campo, Gianluca, Calo, Leonardo, Nassiacos, Daniele, Quadri, Giorgio, Sciahbasi, Alessandro, Silvio Marenzi, Gian Carlo, Reimers, Bernhard, Perna, Gian Piero, Sacca, Salvatore, Fattore, Luciano, Brunelli, Claudio, Picchi, Andrea, Kuramochi, Takehiko, Kondo, Kazuhisa, Aoyama, Takahiko, Kudoh, Takashi, Yamamoto, Tadashi, Takaya, Tomofumi, Mukai, Yasushi, Fukui, Kazuki, Morioka, Nobuyuki, Ando, Kenji, Yamamuro, Atsushi, Morita, Yasuhiro, Koga, Yasuaki, Watanabe, Tetsuya, Sakamoto, Tomohiro, Shibasaki, Taro, Maebuchi, Daisuke, Takahashi, Akihiko, Yonetsu, Taishi, Kakuta, Tsunekazu, Nishina, Hidetaka, Oemrawsingh, Rohit, Dorman, Reinhart, Oude Ophius, Ton, Prins, Paco, al Windy, N.Y.Y., Zoet-Nugteren, S.K., Hermanides, Rik, van Eck, Martijn, Scherptong, Roderick, Cornel, J.H., Damman, Peter, Bech, Gerhard, Torquay, R., Kietselaer, Bas, Grzelakowski, Pawel, Krzysztof, Dyrbus, Budaj, Andrzej, Miekus, Pawel, Przybylski, Andrzej, Zarebinski, Maciej, Balsam, Pawel, Szachniewicz, Joanna, Gierlotka, Marek, Tycinska, Agnieszka, Iniguez Romo, Andres, Fernandez Ortiz, Antonio, Carrasquer Cucarella, Anna, Sanmartin Fernandez, Marcelo, Sionis, Alessandro, Bueno Zamora, Hector, Ferreiro Gutierrez, Jose Luis, Almenar, Luis, Ferreira Gonzalez, Ignacio, Pascual Figal, Domingo A., Almendro Delia, Manuel, Jimenez Fernandez, Miriam, Skeppholm, Mika, Zedigh, Crister, Angeras, Oskar, Lauermann, Jorg, Erlinge, David, Gustafsson, Robin, Mooe, Thomas, Utreras, Alejandro, James, Stefan, Grimfjard, Per, Pedrazzini, Giovanni, Mach, Francois, Fournier, Stephane, Haegeli, Laurent, Beer, Jurg H., Leibundgut, Gregor, Kobza, Richard, Kaiser, Christoph, Kunadian, Vijay, Al-Lamee, Rasha, Gorog, Diana, Khan, Sohail, Trevelyan, Jasper, Toor, Iqbal, Smith, James, Purushottam, Bhaskar, Treasure, Charles, Arena, Frank, Vedere, Amarnath, Henderson, David, Gilani, Syed, Jones, Alonzo, Carrillo-Jimenez, Rodolfo, Gillespie, Eve, Marhefka, Gregary, Wang, David, Olson, Charles, Bloom, Stephen, Iftikhar, Faizan, Brabham, David, McGinty, John, Thompson, Charles, Talano, James, Ginete, Wilson, Williams, Marcus, Masud, Ali, Ariani, Mehrdad, Bitar, Fahed, Wang, Thomas, and Samuelson, Bradley
- Published
- 2022
- Full Text
- View/download PDF
7. Smoking cessation after coronary angiography and percutaneous coronary intervention.
- Author
-
Ramotowski, Bogumił, Foryś, Weronika J., Dzida, Marzena, Dziekan-Wisławska, Kinga, Lenarczyk, Ewelina, and Budaj, Andrzej
- Published
- 2022
- Full Text
- View/download PDF
8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
- Author
-
Hagström, Emil, Steg, P. Gabriel, Szarek, Michael, Bhatt, Deepak L., Bittner, Vera A., Danchin, Nicolas, Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Liberopoulos, Evangelos, Marx, Nikolaus, McGinniss, Jennifer, Manvelian, Garen, Pordy, Robert, Scemama, Michel, White, Harvey D., Zeiher, Andreas M., Schwartz, Gregory G., Schwartz, Gregory G., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Szarek, Michael, White, Harvey D., Zeiher, Andreas M., Tricoci, Pierluigi, Roe, Matthew T., Mahaffey, Kenneth W., Edelberg, Jay M., Hanotin, Corinne, Lecorps, Guillaume, Moryusef, Angèle, Pordy, Robert, Sasiela, William J., Tamby, Jean-François, Diaz, Rafael, Aylward, Philip E, Drexel, Heinz, Sinnaeve, Peter, Dilic, Mirza, Lopes, Renato D., Gotcheva, Nina N, Goodman, Shaun G., Prieto, Juan-Carlos, Yong, Huo, López-Jaramillo, Patricio, Pećin, Ivan, Reiner, Zeljko, Ostadal, Petr, Poulsen, Steen Hvitfeldt, Viigimaa, Margus, Nieminen, Markku S, Danchin, Nicolas, Chumburidze, Vakhtang, Marx, Nikolaus, Liberopoulos, Evangelos, Carlos, Pablo, Valdovinos, Montenegro, Tse, Hung-Fat, Kiss, Robert Gabor, Xavier, Denis, Zahger, Doron, Valgimigli, Marco, Kimura, Takeshi, Kim, Hyo Soo, Kim, Sang-Hyun, Erglis, Andrejs, Laucevicius, Aleksandras, Kedev, Sasko, Yusoff, Khalid, Ramos López, Gabriel Arturo, Alings, Marco, White, Harvey D., Halvorsen, Sigrun, Correa Flores, Roger M, Sy, Rody G., Budaj, Andrzej, Morais, Joao, Dorobantu, Maria, Karpov, Yuri, Ristic, Arsen D., Chua, Terrance, Murin, Jan, Fras, Zlatko, Dalby, Anthony J, Tuñón, José, de Silva, H. Asita, Hagström, Emil, Landmesser, Ulf, Müller, Christian, Chiang, Chern-En, Sritara, Piyamitr, Guneri, Sema, Parkhomenko, Alexander, Ray, Kausik K., Moriarty, Patrick M., Roe, Matthew T., Vogel, Robert, Chaitman, Bernard, Kelsey, Sheryl F., Olsson, Anders G., Rouleau, Jean-Lucien, Simoons, Maarten L., Alexander, Karen, Meloni, Chiara, Rosenson, Robert, Sijbrands, Eric J.G., Tricoci, Pierluigi, Alexander, John H., Armaganijan, Luciana, Bagai, Akshay, Bahit, Maria Cecilia, Brennan, J. Matthew, Clifton, Shaun, DeVore, Adam D., Deloatch, Shalonda, Dickey, Sheila, Dombrowski, Keith, Ducrocq, Grégory, Eapen, Zubin, Endsley, Patricia, Eppinger, Arleen, Harrison, Robert W., Hess, Connie Ng, Hlatky, Mark A., Jordan, Joseph Dedrick, Knowles, Joshua W., Kolls, Bradley J., Kong, David F., Leonardi, Sergio, Lillis, Linda, Lopes, Renato D., Maron, David J., Mahaffey, Kenneth W., Marcus, Jill, Mathews, Robin, Mehta, Rajendra H., Mentz, Robert J., Moreira, Humberto Graner, Patel, Chetan B., Pereira, Sabrina Bernardez, Perkins, Lynn, Povsic, Thomas J., Puymirat, Etienne, Roe, Matthew T., Jones, William Schuyler, Shah, Bimal R., Sherwood, Matthew W., Stringfellow, Kenya, Sujjavanich, Darin, Toma, Mustafa, Trotter, Charlene, van Diepen, Sean F.P., Wilson, Matthew D., Tze-Kay Yan, Andrew, Schiavi, Lilia B, Garrido, Marcelo, Alvarisqueta, Andrés F, Sassone, Sonia A, Bordonava, Anselmo P, Alves De Lima, Alberto E, Schmidberg, Jorge M, Duronto, Ernesto A, Caruso, Orlando C, Novaretto, Leonardo P, Hominal, Miguel Angel, Montaña, Oscar R, Caccavo, Alberto, Gomez Vilamajo, Oscar A, Lorenzatti, Alberto J, Cartasegna, Luis R, Paterlini, Gustavo A, Mackinnon, Ignacio J, Caime, Guillermo D, Amuchastegui, Marcos, Salomone, Oscar, Codutti, Oscar R, Jure, Horacio O, Bono, Julio OE, Hrabar, Adrian D, Vallejos, Julio A, Ahuad Guerrero, Rodolfo A, Novoa, Federico, Patocchi, Cristian A, Zaidman, Cesar J, Giuliano, Maria E, Dran, Ricardo D, Vico, Marisa L, Carnero, Gabriela S, Guzman, Pablo N, Medrano Allende, Juan C, Garcia Brasca, Daniela F, Bustamante Labarta, Miguel H, Nani, Sebastian, Blumberg, Eduardo DS, Colombo, Hugo R, Liberman, Alberto, Fuentealba, Victorino, Luciardi, Hector L, Waisman, Gabriel D, Berli, Mario A, Garcia Duran, Ruben O, Cestari, Horacio G, Luquez, Hugo A, Giordano, Jorge A, Saavedra, Silvia S, Zapata, Gerardo, Costamagna, Osvaldo, Llois, Susana, Waites, Jonathon H, Collins, Nicholas, Soward, Allan, Aylward, Philip E, Hii, Chris LS, Aylward, Philip E, Shaw, James, Arstall, Margaret A, Horowitz, John, Ninio, Daniel, Rogers, James F, Colquhoun, David, Oqueli Flores, Romulo E, Roberts-Thomson, Philip, Raffel, Owen, Lehman, Sam J, Aroney, Constantine, Coverdale, Steven GM, Garrahy, Paul J, Starmer, Gregory, Sader, Mark, Carroll, Patrick A, Dick, Ronald, Zweiker, Robert, Hoppe, Uta, Drexel, Heinz, Huber, Kurt, Berger, Rudolf, Delle-Karth, Georg, Frey, Bernhard, Weidinger, Franz, Faes, Dirk, Hermans, Kurt, Pirenne, Bruno, Leone, Attilio, Hoffer, Etienne, Sinnaeve, Peter, Vrolix, Mathias CM, Wolf, Luc De, Wollaert, Bart, Castadot, Marc, Dujardin, Karl, Beauloye, Christophe, Vervoort, Geert, Striekwold, Harry, Convens, Carl, Roosen, John, Barbato, Emanuele, Claeys, Marc, Cools, Frank, Terzic, Ibrahim, Barakovic, Fahir, Midzic, Zlatko, Pojskic, Belma, Fazlibegovic, Emir, Dilic, Mirza, Durak-Nalbantic, Azra, Kulić, Mehmed, Vulic, Dusko, Muslibegovic, Adis, Goronja, Boris, Reis, Gilmar, Sousa, Luciano, Nicolau, Jose C, Giorgeto, Flavio E, Silva, Ricardo P, Maia, Lilia Nigro, Rech, Rafael, Rossi, Paulo RF, Cerqueira, Maria José AG, Duda, Norberto, Kalil, Renato, Kormann, Adrian, Abrantes, José Antonio M, Filho, Pedro Pimentel, Soggia, Ana Priscila, de Santos, Mayler ON, Neuenschwander, Fernando, Bodanese, Luiz C, Michalaros, Yorghos L, Eliaschewitz, Freddy G, Vidotti, Maria H, Leaes, Paulo E, Botelho, Roberto V, Kaiser, Sergio, Manenti, Euler Roberto F Fernandes, Precoma, Dalton B, Moura Jorge, Jose C, Silva, Pedro, Silveira, Jose A, Saporito, Wladmir, Neto, Jose A Marin, Feitosa, Gilson S, Ritt, Luiz Eduardo F, de Souza, Juliana A, Costa, Fernando, Souza, Weimar KSB, Reis, Helder JL, Lopes, Renato D., Machado, Leandro, Aidar Ayoub, José Carlos, Todorov, Georgi V, Nikolov, Fedya P, Velcheva, Elena S, Tzekova, Maria L, Benov, Haralambi O, Petranov, Stanislav L, Tumbev, Haralin S, Shehova-Yankova, Nina S, Markov, Dimitar T, Raev, Dimitar H, Mollov, Mihail N, Kichukov, Kostadin N, Ilieva- Pandeva, Katya A, Gotcheva, Nina N, Ivanova, Raya, Gospodinov, Maryana, Mincheva, Valentina M, Lazov, Petar V, Dimov, Bojidar I, Senaratne, Manohara, Stone, James, Kornder, Jan, Pearce, Stephen, Dion, Danielle, Savard, Daniel, Pesant, Yves, Pandey, Amritanshu, Robinson, Simon, Gosselin, Gilbert, Vizel, Saul, Hoag, Gordon, Bourgeois, Ronald, Morisset, Anne, Sabbah, Eric, Sussex, Bruce, Kouz, Simon, MacDonald, Paul, Diaz, Ariel, Michaud, Nicolas, Fell, David, Leung, Raymond, Vuurmans, Tycho, Lai, Christopher, Nigro, Frank, Davies, Richard, Nogareda, Gustavo, Vijayaraghavan, Ram, Ducas, John, Lepage, Serge, Mehta, Shamir, Cha, James, Dupuis, Robert, Fong, Peter, Lutchmedial, Sohrab, Rodes-Cabau, Josep, Fadlallah, Hussein, Cleveland, David, Huynh, Thao, Bata, Iqbal, Hameed, Adnan, Pincetti, Cristian, Potthoff, Sergio, Prieto, Juan C, Acevedo, Monica, Aguirre, Arnoldo, Vejar, Margarita, Yañez, Mario, Araneda, Guillermo, Fernandez, Mauricio, Perez, Luis, Varleta, Paola, Florenzano, Fernando, Huidobro, Laura, Raffo, Carlos A, Olivares, Claudia, Nahuelpan, Leonardo, Montecinos, Humberto, Chen, Jiyan, Dong, Yugang, Huang, Weijian, Wang, Jianzhong, Huang, Shi’An, Yao, Zhuhua, Li, Xiang, Cui, Lan, Lin, Wenhua, Sun, Yuemin, Wang, Jingfeng, Li, Jianping, Zhang, Xuelian, Zhu, Hong, Chen, Dandan, Huang, Lan, Dong, Shaohong, Su, Guohai, Xu, Biao, Su, Xi, Cheng, Xiaoshu, Lin, Jinxiu, Zong, Wenxia, Li, Huanming, Feng, Yi, Xu, Dingli, Yang, Xinchun, Ke, Yuannan, Lin, Xuefeng, Zhang, Zheng, Zheng, Zeqi, Luo, Zhurong, Chen, Yundai, Ding, Chunhua, Zhong, Yi, Zheng, Yang, Li, Xiaodong, Peng, Daoquan, Zhao, Shuiping, Li, Ying, Liu, Xuebo, Wei, Meng, Liu, Shaowen, Yu, Yihua, Qu, Baiming, Jiang, Weihong, Zhou, Yujie, Zhao, Xingsheng, Yuan, Zuyi, Guo, Ying, Xu, Xiping, Shi, Xubo, Ge, Junbo, Fu, Guosheng, Bai, Feng, Fang, Weiyi, Shou, Xiling, Yang, Xiangjun, Wang, Jian’An, Xiang, Meixiang, Sun, Yingxian, Lu, Qinghua, Zhang, Ruiyan, Zhu, Jianhua, Xu, Yizhou, Fan, Zhongcai, Li, Tianchang, Wu, Chun, Jaramillo, Nicolas, Vallejo, Gregorio Sanchez, Luna Botia, Diana C, Lopez, Rodrigo Botero, De Salazar, Dora I Molina, Bonfanti, Alberto J Cadena, Aroca, Carlos Cotes, Higuera, Juan Diego, Blanquicett, Marco, Barrera Silva, Sandra I, Garcia Lozada, Henry J, Coronel Arroyo, Julian A, Accini Mendoza, Jose L, Fernandez Ruiz, Ricardo L, Quintero Ossa, Alvaro M., Manzur Jatin, Fernando G, Sotomayor Herazo, Aristides, Parada, Jeffrey Castellanos, Arambula, Rafael Suarez, Urina Triana, Miguel A, Trujillo, Angela M Fernandez, Strozzi, Maja, Car, Siniša, Miličić, Davor, Lovrić Benčić, Martina, Pintarić, Hrvoje, Prvulović, Đeiti, Šikić, Jozica, Peršić, Viktor, Mileta, Dean, Štambuk, Kresimir, Babić, Zdravko, Tomulic, Vjekoslav, Lukenda, Josip, Mejic-Krstulovic, Stanka, Starcevic, Boris, Spinar, Jindrich, Horak, David, Velicka, Zdenek, Alan, David, Machova, Vilma, Linhart, Ales, Novotny, Vojtech, Kaucak, Vladimir, Rokyta, Richard, Naplava, Robert, Coufal, Zdenek, Adamkova, Vera, Podpera, Ivo, Zizka, Jiri, Motovska, Zuzana, Marusincova, Ivana, Ostadal, Petr, Heinc, Petr, Kuchar, Jiri, Povolny, Petr, Matuska, Jiri, Poulsen, Steen H, Raungaard, Bent, Clemmensen, Peter, Bang, Lia E, May, Ole, Bøttcher, Morten, Hove, Jens D, Frost, Lars, Gislason, Gunnar, Larsen, John, Johansen, Peter Betton, Hald, Flemming, Johansen, Peter, Jeppesen, Jørgen, Nielsen, Tonny, Kristensen, Kjeld S, Walichiewicz, Piotr Maria, Lomholdt, Jens D, Klausen, Ib C, Nielsen, Peter Kaiser, Davidsen, Flemming, Videbaek, Lars, Viigimaa, Margus, Soots, Mai, Vahula, Veiko, Hedman, Anu, Soopõld, Üllar, Märtsin, Kaja, Jurgenson, Tiina, Kristjan, Arved, Nieminen, Markku S, Vikman, Saila, Huikuri, Heikki, Airaksinen, Juhani, Coste, Pierre, Ferrari, Emile, Danchin, Nicolas, Morel, Olivier, Montalescot, Gilles, Machecourt, Jacques, Barone-Rochette, Gilles, Mansourati, Jacques, Cottin, Yves, Steg, Ph. Gabriel, Leclercq, Florence, Belhassane, Abdelkader, Delarche, Nicolas, Boccara, Franck, Paganelli, Franck, Clerc, Jérôme, Schiele, Francois, Aboyans, Victor, Probst, Vincent, Berland, Jacques, Lefèvre, Thierry, Chumburidze, Vakhtang, Khintibidze, Irakli, Shaburishvili, Tamaz, Pagava, Zurab, Ghlonti, Ramaz, Lominadze, Zaza, Khabeishvili, George, Hemetsberger, Rayyan, Edward, Kemala, Rauch-Kröhnert, Ursula, Stratmann, Matthias, Appel, Karl-Friedrich, Schmidt, Ekkehard, Omran, Heyder, Stellbrink, Christoph, Dorsel, Thomas, Lianopoulos, Emmanouil, Vöhringer, Hans Friedrich, Marx, Roger, Zirlik, Andreas, Schellenberg, Detlev, Heitzer, Thomas, Laufs, Ulrich, Werner, Christian, Marx, Nikolaus, Gielen, Stephan, Nuding, Sebastian, Winkelmann, Bernhard, Behrens, Steffen, Sydow, Karsten, Karakas, Mahir, Simonis, Gregor, Muenzel, Thomas, Werner, Nikos, Leggewie, Stefan, Böcker, Dirk, Braun- Dullaeus, Rüdiger, Toursarkissian, Nicole, Jeserich, Michael, Weißbrodt, Matthias, Schaeufele, Tim, Weil, Joachim, Völler, Heinz, Waltenberger, Johannes, Natour, Mohammed, Schmitt, Susanne, Müller-Wieland, Dirk, Steiner, Stephan, Heidenreich, Lothar, Offers, Elmar, Gremmler, Uwe, Killat, Holger, Rieker, Werner, Patsilinakos, Sotiris, Kartalis, Athanasios, Manolis, Athanassios, Sionis, Dimitrios, Chachalis, Geargios, Liberopoulos, Evangelos, Skoumas, Ioannis, Athyros, Vasilios, Vardas, Panagiotis, Parthenakis, Frangkiskos, Hahalis, Georgios, Lekakis, John, Hatzitolios, Apostolos, Fausto Ovando, Sergio R, Montenegro Valdovinos, Pablo Carlos, Arango Benecke, Juan L, Rodriguez De Leon, Edgar R, Yan, Bryan PY, Siu, David CW, Turi, Tibor, Merkely, Bela, Gabor Kiss, Robert, Ungi, Imre, Lupkovics, Geza, Nagy, Lajos, Katona, András, Édes, István, Müller, Gábor, Horvath, Iván, Kapin, Tibor, Szigeti, Zsolt, Faluközy, József, Kumbla, Mukund, Sandhu, Manjinder, Annam, Sharath, Reddy Proddutur, Naveen, Regella, Reddy, Premchand, Rajendra K, Mahajan, Ajaykumar, Pawar, Sudhir, Abhyanakar, Atul D, Kerkar, Prafulla, Govinda, Ravishankar A, Oomman, Abraham, Sinha, Dhurjati, Patil, Sachin N, Kahali, Dhiman, Sawhney, Jitendra, Joshi, Abhijeet B, Chaudhary, Sanjeev, Harkut, Pankaj, Guha, Santanu, Porwal, Sanjay, Jujjuru, Srimannarayana, Pothineni, Ramesh B, Monteiro, Minguel R, Khan, Aziz, Iyengar, Shamanna S, Grewal, Jasprakash Singh, Chopda, Manoj, Fulwani, Mahesh C, Patange, Dr. Aparna, Sachin, Patil, Chopra, Vijay K, Goyal, Naresh K, Shinde, Rituparna, Manakshe, Gajendra V, Patki, Nitin, Sethi, Sumeet, Munusamy, Vengatesh, Sunil Thanvi, Sunil Karnaand, Adhyapak, Srilakshmi, Patil, Chandrakant, Pandurangi, Ulhas, Mathur, Rishabh, Gupta, Jugal, Kalashetti, Suhas, Bhagwat, Ajit, Raghuraman, Bagirath, Kumar Yerra, Shiv, Bhansali, Prasant, Borse, Rohidas, Rahul, Patil, Das, Srihari, Kumar, Vinay, Abdullakutty, Jabir, Saathe, Shireesh, Palimkar, Priya, Abdullkutty, Jabir, Sathe, Shireesh, Atar, Shaul, Shechter, Michael, Mosseri, Morris, Arbel, Yaron, Ehud, Chorin, Ofer, Havakuk, Lotan, Chaim, Rosenschein, Uri, Katz, Amos, Henkin, Yaakov, Francis, Adi, Klutstein, Marc, Nikolsky, Eugenia, Zukermann, Robert, Turgeman, Yoav, Halabi, Majdi, Marmor, Alon, Kornowski, Ran, Jonas, Michael, Amir, Offer, Hasin, Yonathan, Rozenman, Yoseph, Fuchs, Shmuel, Zvi, Vered, Hussein, Osamah, Gavish, Dov, Vered, Zvi, Caraco, Yoseph, Elias, Mazen, Tov, Naveh, Wolfovitz, Efrat, Lishner, Michael, Elias, Nizar, Piovaccari, Giancarlo, Pellegrin, Annamaria De, Garbelotto, Raffaella, Guardigli, Gabriele, Marco, Valgimigli, Licciardello, Giovanni, Auguadro, Carla, Scalise, Filippo, Cuccia, Claudio, Salvioni, Alessandro, Musumeci, Giuseppe, Senni, Michelle, Calabrò, Paolo, Novo, Salvatore, Faggiano, Pompilio, Metra, Marco, De Cesare, Nicoletta B, Berti, Sergio, Puccioni, Enrico, Galvani, Marcello, Tespili, Maurizio, Piatti, Piermarco, Palvarini, Michela, Luca, Giuseppe De, Violini, Roberto, Leo, Alessandro De, Olivari, Zoran, Filardi, Pasquale Perrone, Ferratini, Maurizio, Racca, Vittorio, Dai, Kazuoki, Shimatani, Yuji, Kamiya, Haruo, Ando, Kenji, Takeda, Yoshihiro, Morino, Yoshihiro, Hata, Yoshiki, Kimura, Kazuo, Kishi, Koichi, Michishita, Ichiro, Uehara, Hiroki, Higashikata, Toshinori, Hirayama, Atsushi, Hirooka, Keiji, Doi, Yasuji, Sakagami, Satoru, Taguchi, Shuichi, Koike, Akihiro, Fujinaga, Hiroyuki, Koba, Shinji, Kozuma, Ken, Kawasaki, Tomohiro, Ono, Yujiro, Shimizu, Masatoshi, Katsuda, Yousuke, Wada, Atsuyuki, Shinke, Toshiro, Kimura, Takeshi, Ako, Junya, Fujii, Kenshi, Takahashi, Toshiyuki, Nakao, Koichi, Furukawa, Yutaka, Sugino, Hiroshi, Tamura, Ritsu, Mano, Toshiaki, Uematsu, Masaaki, Utsu, Noriaki, Ito, Kashima, Haraguchi, Takuya, Sato, Katsuhiko, Ueda, Yasunori, Nishibe, Akira, Fujimoto, Kazuteru, Masutani, Motomaru, Nishibe, Akira, Fujimoto, Kazuteru, Yoon, Jung Han, Kim, Sang-Hyun, Kim, Hack-Lyoung, Sik Park, Hun, Chae, In-Ho, Kim, Moo Hyun, Jeong, Myung Ho, Rha, Seungwoon, Kim, Chongjin, Kim, Hyo-Soo, Kim, Hae Young, Hong, Taekjong, Tahk, Seung-Jea, Kim, Youngkwon, Busmane, Arija, Pontaga, Natalija, Strelnieks, Aldis, Mintale, Iveta, Sime, Iveta, Petrulioniene, Zaneta, Kavaliauskiene, Roma, Jurgaitiene, Ruta, Sakalyte, Gintare, Slapikas, Rimvydas, Norkiene, Sigute, Misonis, Nerijus, Kibarskis, Aleksandras, Kubilius, Raimondas, Bojovski, Stojko, Kedev, Sasko, Lozance, Nensi, Kjovkaroski, Aleksandar, Doncovska, Snezana, Ong, Tiong Kiam, Kasim, Sazzli, Maskon, Oteh, Kandasamy, Balachandran, Yusoff, Khalid, Liew, Houng B, Wan Mohamed, Wan Mohd Izani, Castillo, Armando García, Ramos López, Gabriel Arturo, Calvillo, Jorge Carrillo, Campos, Pedro Fajardo, Núñez Fragoso, Juan Carlos, Bayram Llamas, Edmundo Alfredo, Alcocer Gamba, Marco Antonio, Madrigal, Jaime Carranza, González Salas, Luis Gerardo, Rosas, Enrique López, González Díaz, Belinda, Vázquez, Eduardo Salcido, Nacoud Ackar, Alfredo, Llamas Esperón, Guillermo Antonio, Martínez Sánchez, Carlos Rodolfo, De Leon, María Guerrero, Suarez Otero, Rodrigo, Salmón, Guillermo Fanghänel, Pérez Ríos, Jesús Antonio, Garza Ruíz, José Angel, Alings, Marco, Breedveld, Robert W, Feenema-Aardema, Margriet, Borger-Van Der Burg, Alida, Hoogslag, Pieter AM, Suryapranata, Harry, Oomen, Antonius, Van Haelst, Paulus, Feenema-Aradema, Margriet, Wiersma, Jacobijne J, Basart, Dirk, Van Der Wal, Ruud MA, Zwart, Peter, Monraats, Pascalle, Van Kesteren, Henricus, Karalis, Ioannis, Jukema, Johan, Verdel, Gerardus JE, Brueren, Bart RG, Troquay, Roland PTh, Viergever, Eric P, Al-Windy, Nadea YY, Bartels, Gerard L, Cornel, Jan H, Hermans, Walter RM, Herrman, Johannes PR, Bos, Robert J, Groutars, Reginald GEJ, Van Der Zwaan, Coenraad C, Kaplan, Refik, Ronner, Eelko, Groenemeijer, Bjorn E, Bronzwaer, Patrick NA, Liem, Anho AH, Rensing, Bernard JWM, Bokern, Marcel JJA, Nijmeijer, Remco, Hersbach, Ferry MRJ, Willems, Frank F, Gosselink, Antonius TM, Rasoul, Saman, Elliott, John, Wilkins, Gerard, Fisher, Raewyn, Scott, Douglas, Hart, Hamish, Stewart, Ralph, Harding, Scott, Ternouth, Ian, Fisher, Nicholas, Wilson, Samuel, Aitken, Denise, Anscombe, Russell, Davidson, Laura, Tomala, Tadeusz, Nygård, Ottar, Sparby, Jon Arne, Andersen, Kjell, Gullestad, Lars, Jortveit, Jarle, Munk, Peter S, Singsaas, Erlend gyllensten, Halvorsen, Sigrun, Hurtig, Ulf, Correa Flores, Roger M, Calderon Ticona, Jorge R, Durand Velasquez, Julio R, Negron Miguel, Sandra A, Sanabria Perez, Enrique S, Carrion Chambilla, Jesus M, Chavez Ayala, Carlos A, Castillo Leon, Reynaldo P, Vargas GonzalesC, Rolando J, Hernandez Zuniga, Jose D, Camacho Cosavalente, Luis A, Bravo Mannucci, Jorge E, Landeo, Javier Heredia, Llerena Navarro, Nassip C, Roldan Concha, Yudy M, Rodriguez Chavez, Víctor E, Anchante Hernandez, Henry A, Zea Nunez, Carlos A, Ramos, Walter Mogrovejo, Ferrolino, Arthur, Sy, Rosa Allyn G, Tirador, Louie, Sy, Rody G., Matiga, Generoso, Coching, Raul Martin, Bernan, Alisa, Rogelio, Gregorio, Morales, Dante D., Tan, Edgar, Sulit, Dennis Jose, Wlodarczak, Adrian, Skonieczny, Grzegorz, Pawlowicz, Lidia, Wojewoda, Pawel, Busz-Papiez, Benita, Bednarski, Janusz, Goch, Aleksander, Staneta, Pawel, Dulak, Elzbieta, Budaj, Andrzej, Saminski, Krzysztof, Krasowski, Wlodzimierz, Sudnik, Wanda, Zurakowski, Aleksander, Skorski, Marcin, Lysek, Roman, Miklaszewicz, Beata, Lipko, Jan Andrzej, Kostarska-Srokosz, Edyta, Piepiorka, Marek, Drzewiecka, Anna, Stasiewski, Arkadiusz, Blicharski, Tomasz, Bystryk, Leszek, Szpajer, Michal, Korol, Marek, Czerski, Tomasz, Gniot, Jacek, Lubinski, Andrzej, Gorny, Jerzy, Franek, Edward, Raczak, Grzegorz, Szwed, Hanna, Monteiro, Pedro, Mesquita Bastos, Jose, Pereira, Helder H, Morais, Joao, Seixo, Filipe, Mendonça, Carlos, Botelho, Ana, Caetano, Francisca, Minescu, Bogdan, Istratoaie, Octavian, Tesloianu, Dan N, Dorobantu, Maria, Cristian, Gabriel, Dumitrescu, Silviu, Podoleanu, Cristian GC, Constantinescu, Mircea CA, Bengus, Cristina M, Militaru, Constantin, Rosu, Doina, Parepa, Irinel R, Matei, Adrian V, Alexandru, Tom M, Malis, Mihaela, Coman, Ioan, Shvarts, Yury, Orlikova, Olga, Kobalava, Zhanna, Barbarash, Olga L, Markov, Valentin, Lyamina, Nadezhda, Gordienko, Alexander, Zrazhevsky, Konstantin, Vishnevsky, Alexander Y, Gurevich, Victor, Stryuk, Raisa, Lomakin, Nikita V, Bokarev, Igor, Khlevchuk, Tatiana, Shalaev, Sergey, Khaisheva, Larisa, Chizhov, Petr, Viktorova, Inna, Osokina, Natalya, Shchekotov, Vladimir, Akatova, Evgenia, Chumakova, Galina, Libov, Igor, Voevoda, Mikhail I, Tretyakova, Tatyana V, Baranov, Evgeny, Shustov, Sergey, Yakushin, Sergey, Gordeev, Ivan, Khasanov, Niiaz, Reshetko, Olga, Sotnikova, Tatiana, Molchanova, Olga, Nikolaev, Konstantin, Gapon, Liudmila, Baranova, Elena, Kosmachova, Elena, Karpov, Yuriy, Karpov, Yuri, Povzun, Anton, Egorova, Liudmila, Tyrenko, Vadim V, Ivanov, Igor G, Ilya, Masterov, Kanorsky, Sergey, Simic, Dragan, Ivanovic, Nikola, Davidovic, Goran, Tasic, Nebojsa, Asanin, Milika R., Stojic, Stevo, Apostolovic, Svetlana R., Ilic, Stevan, Tosic, Biljana Putnikovic, Stankovic, Aleksandar, Arandjelovic, Aleksandra, Radovanovic, Slavica, Todic, Branislava, Ristic, Arsen D., Balinovac, Jovan, Dincic, Dragan V., Seferovic, Petar, Karadzic, Ana, Dodic, Slobodan, Dimkovic, Sinisa, Jakimov, Tamara, Poh, Kian-Keong, Yee Ong, Hean, Tang I-Shing, Justin, Micko, Karol, Nociar, Jan, Pella, Daniel, Fulop, Peter, Hranai, Marian, Palka, Juraj, Mazur, Juraj, Majercák, Ivan, Dzupina, Andrej, Fazekas, František, Gonsorcik, Jozef, Bugan, Viliam, Murin, Jan, Selecky, Juraj, Kamensky, Gabriel, Strbova, Jaroslava, Smik, Rudolf, Dukat, Andrej, Olexa, Peter, Žuran, Ivan, Poklukar, Janez, Šuligoj, Nataša Černič, Cevc, Matija, Fras, Zlatko, Cyster, Henry P, Ranjith, Naresh, Corbett, Clive, Bayat, Junaid, Makoali Makotoko, Ellen, du Toit Theron, Hendrik, Kapp, Ilse E, de V Basson, Matthys M, Lottering, Hanlie, Aswegen, Dina Van, Van Zyl, Louis J, Sebastian, Peter J, Pillay, Thayabran, Saaiman, Jan A, Commerford, Patrick J, Cassimjee, Soraya, Riaz, Garda, Ebrahim, Iftikhar O, Sarvan, Mahomed, Mynhardt, Joseph H, Dalby, Anthony J, Reuter, Helmuth, Moodley, Rajendran, Vida, Manuel, Fillat, Angel R. Cequier, Peris, Vicente Bodí, Jimenez, Francisco Fuentes, Marín, Francisco, Cruz Fernández, Jose M, Hidalgo Urbano, Rafael Jesus, Gil-Extremera, Blas, Toledo, Pablo, Worner Diz, Fernando, Garcia-Dorado, David, Iñiguez, Andres, Gonzalez-Juanatey, Jose R, Portales, Javier Fernandez, Murillo, Fernando Civeira, Pericas, Laia Matas, Zamorano, Jose Luis, De Mora Martin, Manuel, Cortada, Jordi Bruguera, Alonso Martin, Joaquin J, Serrano Antolin, Jose Maria, De Berrazueta Fernández, José R, Vázquez de Prada, José Antonio, Díaz Fernández, Jose Francisco, García Lledó, José Alberto, Cosín Sales, Juan, Rodriguez, Javier Botas, Tragant, Gabriel Gusi, Benedicto, Amparo, Gonzalez-Juanatey, Carlos, Camprubí Potau, Mercedes, Perez, Ignacio Plaza, De La Tassa, César Morís, Rincon, Pablo Loma-Osorio, Recena, Javier Balaguer, Escudier, Juan M, Payeras, Antonio Coca, Orcajo, Norberto Alonso, Constantine, Godwin, Haniffa, Ruvaiz, Tissera, Nirmali, Amarasekera, Stanley, Ponnamperuma, Chandrike, Fernando, Nimali, Fernando, Kaputella, Jayawardena, Jayanthimala, Wijeyasingam, Santharaj, Ranasinghe, Gotabhaya, Ekanayaka, Ruvan, Mendis, Sepalika, Senaratne, Vajira, Mayurathan, Gnanamoorthy, Rajapaksha, Ajantha, Sirisena, Thilak, Herath, Jagath I, Amarasena, Naomali, Berglund, Stefan, Rasmanis, Gundars, Hagström, Emil, Vedin, Ola, Witt, Nils, Mourtzinis, Georgios, Nicol, Peter, Hansen, Ole, Romeo, Stefano, Jensen, Steen Agergaard, Torstensson, Ingemar, Ahremark, Ulf, Sundelin, Torbjörn, Moccetti, Tiziano, Müller, Christian, Mach, Francois, Binde, Ronald, Landmesser, Ulf, Gämperli, Oliver, Chiang, Chern-En, Tsai, Wei- Chuan, Ueng, Kwo-Chang, Lai, Wen-Ter, Liu, Ming-En, Hwang, Juey- Jen, Yin, Wei-Hsian, Hsieh, I-Chang, Hsieh, Ming-Jer, Hsiang Lin, Wei, Kuo, Jen-Yuan, Huang, Tsuei-Yuan, Fang, Chih-Yuan, Kaewsuwanna, Pinij, Soonfuang, Wasant, Jintapakorn, Woravut, Sukonthasarn, Apichard, Sritara, Piyamitr, Wongpraparut, Nattawut, Sastravaha, Krisada, Sansanayudh, Nakarin, Kehasukcharoen, Wirash, Piyayotai, Dilok, Chotnoparatpat, Paiboon, Camsari, Ahmet, Kultursay, Hakan, Guneri, Sema, Mutlu, Bulent, Ersanli, Murat, Demirtas, Mustafa, Kirma, Cevat, Ural, Ertan, Koldas, Lale, Karpenko, Oleksandr, Prokhorov, Alexander, Vakaluyk, Ihor, Myshanych, Halyna, Reshotko, Dmytro, Batushkin, Valeriy, Rudenko, Leonid, Kovalskyi, Ihor, Kushnir, Mykola, Tseluyko, Vira, Mostovoy, Yuriy, Stanislavchuk, Mykola, Kyiak, Yulian, Karpenko, Yuriy, Malynovsky, Yaroslav, Klantsa, Andriy, Kutniy, Oles, Amosova, Ekaterina, Tashchuk, Viktor, Leshchuk, Oleh, Parkhomenko, Alexander, Rishko, Mykola, Kopytsya, Mykola, Yagensky, Andriy, Vatutin, Mykola, Bagriy, Andriy, Barna, Olga M, Ushakov, Olexiy, Dzyak, Georgiy, Goloborodko, Borys, Rudenko, Anatolii, Zheleznyy, Volodymyr, Trevelyan, Jasper, Zaman, Azfar, Lee, Kaeng, Moriarty, Andrew, Aggarwal, Rajesh K, Clifford, Piers, Wong, Yuk- Ki, Iqbal, Syed MR, Subkovas, Eduardas, Braganza, Denise, Sarkar, David, Storey, Robert, Griffiths, Huw, Mcclure, Sam, Muthusamy, Rangasamy, Smith, Simon, Kurian, John, Levy, Terry, Barr, Craig, Kadr, Honer, Gerber, Robert, Simaitis, Audrius, Soran, Handrean, Brodison, Adrian, Ayaz, Mohammad, Cheema, Muhammad, Oliver, Richard, Thackray, Simon, Mudawi, Telal, Rahma, Gohar, Sultan, Ayyaz, Reynolds, Timothy, Sharman, David, Spriging, david, Butler, Rob, Wilkinson, Peter, Lip, Gregory YH, Ossei-Gerning, Nicholas, Vardi, Gil, Baldari, Duccio, Brabham, David, Treasure II, Charles, Dahl, Charles, Palmer, Bruce, Wiseman, Alan, Khan, Abul, Puri, Sanjeev, Mohart, Ann Elizabeth, Ince, Carlos, Flores, Enrique, Wright, Scott, Cheng, Shi-Chi, Rosenberg, Michael, Rogers, William, Kosinski, Edward, Forgosh, Les, Waltman, Jonathan, Shoukfeh, Mohammad, Dagher, Georges, Cambier, Patrick, Lieber, Ira, Kumar, Priya, East, Cara, Krichmar, Perry, Hasan, Mian, White, Lindsey, Knickelbine, Thomas, Haldis, Thomas, Gillespie, Eve, Amidon, Thomas, Suh, David, Arif, Imran, Abdallah, mouhamad, Akhter, Faiq, Carlson, Eric, D’Urso, Michael, El- Ahdab, Fadi, Nelson, William, Moriarty, Katie, Harris, Barry, Cohen, Steven, Carter, Luther, Doty, Daniel, Sabatino, Kenneth, Haddad, Tariq, Rao, Sunder, Mulkay, Angel, Jovin, Ion, Klancke, Kim, Malhotra, Vinay, Devarapalli, Sai K, Koren, Michael, Chandna, Harish, Dodds III, George, Goraya, Tauqir, Bengston, James, Janik, Matthew, Moran, Joseph, Sumner, Andrew, Kobayashi, John, Davis, William, Yazdani, Shahram, Pasquini, John, Thakkar, Maitreya, Vedere, Amarnath, Leimbach, Wayne, Rider, James, fenton, Sarah, Singh, Narendra, Shah, Anil V, Moriarty, Patrick M., Janosik, Denise, Pepine, Carl, Berman, Brett, Gelormini, Joseph, Daniels, Christopher, Richard, Kerensky, Keating, Friederike, Kondo, Nicholas I, Shetty, Sanjay, Levite, Howard, Waider, Winfried, Takata, Theodore, Abu-Fadel, Mazen, Shah, Vipul, Aggarwal, Rahul, Kumar, Anil, Hattler, Brack, Do, Rose, Link, Chad, Bortnick, Anna, Kinzfogl III, George, Ghitis, Arnold, Larry, John, Teufel, Edward, Kuhlman, Peter, Mclaurin, Brent, Zhang, Wenwu, Thew, Stephen, Abbas, Jalal, White, Matthew, Islam, Othman, Subherwal, Sumeet, Ranadive, Nandkishore, Vakili, Babak, Gring, Christian, Henderson, David, Schuchard, Timothy, Farhat, Naim, Kline, Geoffrey, Mahal, Sharan, Whitaker, Jack, Speirs, Shawn, Andersen, Rolf, Daboul, Nizar, Horwitz, Phillip, Zahr, Firas, Ponce, George, Jafar, Zubair, Mcgarvey, Joseph, Panchal, Vipul, Voyce, Stephen, Blok, Thomas, Sheldon, William, Azizad, Masoud M, Schmalfuss, Carsten, Picone, Mark, Pederson, Robert, Herzog, William, Friedman, Keith, Lindsey, Jason, Timothy, Eichenlaub, Leonard, Parilak, Lepor, Norman, El Shahawy, Mahfouz, Weintraub, Howard, Irimpen, Anand, Alonso, Alvaro, May, Wade, Christopher, Daniels, Galski, Thomas, Chu, Alan, Mody, Freny, Ramin, Ebrahimi, Hodes, Zachary, Rossi, Joseph, Rose, Gregory, Fairlamb, James, Lambert, Charles, Raisinghani, Ajit, Abbate, Antonio, Vetrovec, George, King, Marilyn, Carey, Charles, Gerber, Jaime, Younis, Liwa, Park, Hyeun (Tom), Vidovich, Mladen, Knutson, Thomas, Friedman, Dennis, Chaleff, Fred, Loussararian, Arthur, Rozeman, Phillip, Kimmelstiel, Carey, Kuvin, Jeffrey, Silver, Kevin, Foster, Malcolm, Tonnessen, Glen, Espinoza, Andrey, Amlani, Mohamadali, Wali, Andreas, Malozzi, Christopher, Jong, Geert T, Massey, Clara, Wattanakit, Keattiyoat, O’Donnell, Philip J., Singal, Dinesh, Jaffrani, Naseem, Banuru, Sridhar, Fisher, Daniel, Xenakis, Mark, Perlmutter, Neal, Bhagwat, Ravi, Strader, James, Blonder, Ronald, Akyea-Djamson, Ayim, Labroo, Ajay, Lee, Kwan, Marais, H. John, Claxton, Edmund, Weiss, Robert, Kathryn, Rohr, Berk, Martin, Rossi, Peter, Joshi, Parag, Khera, Amit, Khaira, Ajit S, Kumkumian, Greg, Lupovitch, Steven, Purow, Joshua, Welka, Stephen, Hoffman, David, Fischer, Stuart, Soroka, Eugene, Eagerton, Donald, Pancholy, Samir, Ray, Michael, Erenrich, Norman, Farrar, Michael, Pollock, Stewart, French, William J, Diamantis, Steve, Guy, Douglas, Gimple, Lawrence, Neustel, Mark, Schwartz, Steven, Pereira, Edward, Albert, Seals, Spriggs, Douglas, Strain, Janet, Mittal, Suneet, Vo, Anthony, Chane, Majed, Hall, Jason, Vijay, Nampalli, Lotun, Kapildeo, Lester, F. Martin, Nahhas, Ahed, Pope, Theodore, Nager, Paul, Vohra, Rakesh, Sharma, Mukesh, Bashir, Riyaz, Ahmed, Hinan, Berlowitz, Michael, Fishberg, Robert, Barrucco, Robert, Yang, Eric, Radin, Michael, Sporn, Daniel, Stapleton, Dwight, Eisenberg, Steven, Landzberg, Joel, Mcgough, Martin, Turk, Samir, Schwartz, Michael, Sundram, P. Sandy, Jain, Diwakar, Zainea, Mark, Bayron, Carlos, Karlsberg, Ronald, Dohad, Suhail, Lui, Henry, Keen, William, Westerhausen, Donald, Khurana, Sandeep, Agarwal, Himanshu, Birchem, Jessica, Penny, William, Chang, Mark, Murphy, Sherrill, Henry, John, Schifferdecker, Branislav, Gilbert, John M, Chalavarya, Gopal, Eaton, Charles, Schmedtje, John F, Christenson, Stuart, Dotani, Imran, Denham, Douglas, Macdonell, Alexander, Gibson, Paul, Rahman, Aref, Al Joundi, Tammam, Assi, Nizar, Conrad, Gary, Kotha, Purushotham, Love, Michael, Giesler, Gregory, Rubenstein, Howard, Gamil, Dawood, Akright, Laura, Krawczyk, Justine, Cobler, Joanne, Wells, Terry, Welker, James, Foster, Robert, Gilmore, Richard, Anderson, Jay, Jacoby, Douglas, Harris, Bill, Gardner, Geraldine, Dandillaya, Ramprasad, Vora, Kishor, Kostis, John, Hunter, John, Laxson, David, Ball, Eric, Anderson, Jay, Wells, Terry, Vora, Kishor, Ball, Eric, Welker, James, Lopes, Renato D., Egydio, Flavia, Kawakami, Anelise, Oliveira, Janaina, Goodman, Shaun G., Wozniak, Julianna, Matthews, Alexander, Ratky, Caroline, Valiris, Janine, Berdan, Lisa, Hepditch, Anita, Quintero, Kirby, Roe, Matthew T., Rorick, Tyrus, Westbrook, Melissa, Danchin, Nicolas, Bezault, Madeleine, Drouet, Elodie, Simon, Tabassome, White, Harvey D., Alsweiler, Caroline, Sinnaeve, Peter, Luyten, Anne, Aylward, Philip E, Butters, Julie, Griffith, Liddy, Shaw, Michelle, Hagström, Emil, Grunberg, Lena, Szarek, Michael, Islam, Shahidul, Brégeault, Marie-France, Bougon, Nathalie, Faustino, Douglas, Fontecave, Sylvie, Murphy, Judith, Tamby, Jean- Francois, Verrier, Melanie, Agnetti, Veronique, Andersen, Dorthe, Badreddine, Emmy, Bekkouche, Mhamed, Bouancheau, Cecile, Brigui, Imane, Brocklehurst, Maddy, Cianciarulo, Joseph, Devaul, Dawn, Domokos, Szilvia, Gache, Cecile, Gobillot, Caroline, Guillou, Severine, Healy, Jan, Heath, Megan, Jaiwal, Gayatri, Javierre, Carine, Labeirie, Julien, Monier, Myriam, Morales, Ulises, Mrabti, Asmaa, Mthombeni, Bicky, Okan, Betim, Smith, Lucile, Sheller, Jennifer, Sopena, Sebastien, Pellan, Valerie, Benbernou, Fadela, Bengrait, Nafissa, Lamoureux, Maud, Kralova, Katarina, Scemama, Michel, Bejuit, Raphael, Coulange, Anthony, Berthou, Christelle, Repincay, Jérôme, Lorenzato, Christelle, Etienne, Alexis, Gouet, Valerie, Lecorps, Guillaume, Loizeau, Virginie, Normand, Mickael, Ourliac, Anne, Rondel, Christelle, Adamo, Antony, Beltran, Pascale, Barraud, Pauline, Dubois-Gache, Helene, Halle, Benjamin, Metwally, Lamia, Mourgues, Maxime, Sotty, Marc, Vincendet, Marion, Cotruta, Raluca, Chengyue, Zhu, Fournie-Lloret, Dominique, Morrello, Christine, Perthuis, Aurelie, Picault, Patrick, Zobouyan, Isabelle, Colhoun, Helen M., Dempsey, Michael A., and McClanahan, Mark A.
- Published
- 2022
- Full Text
- View/download PDF
9. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial
- Author
-
Zelniker, Thomas A., Wiviott, Stephen D., Mosenzon, Ofri, Goodrich, Erica L., Jarolim, Petr, Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John, Averkov, Oleg, Budaj, Andrzej, Parkhomenko, Alexander, Ray, Kausik K., Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Fredriksson, Martin, Raz, Itamar, Sabatine, Marc S., and Morrow, David A.
- Abstract
IMPORTANCE: Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear. OBJECTIVE: To explore whether N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) levels can identify a subset of patients with T2D at higher risk and who might benefit more from dapagliflozin with regard to atherosclerotic events. DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of the DECLARE-TIMI 58 trial, a randomized clinical trial of dapagliflozin in patients with T2D and either multiple risk factors for atherosclerotic cardiovascular disease (ASCVD; approximately 60%) or established ASCVD (approximately 40%). All patients with available blood samples at randomization were included in these analyses. Data were collected from May 2013 to September 2018, and data were analyzed from May 2019 to June 2022. INTERVENTIONS: Dapagliflozin vs placebo. MAIN OUTCOMES AND MEASURES: Major adverse cardiovascular events (MACE), the composite of myocardial infarction, ischemic stroke, or cardiovascular death, which was one of dual primary outcomes of the main trial. RESULTS: Of 14 565 included patients, 9143 (62.8%) were male, and the mean (SD) age was 63.9 (6.8) years. When tested individually in a multivariable model for MACE risk, NT-proBNP and hsTnT were each significantly associated with the risk of MACE (adjusted hazard ratio [aHR] per 1 SD in log-transformed biomarker: NT-proBNP, 1.62; 95% CI, 1.49-1.76; hsTnT: 1.59; 95% CI, 1.46-1.74). The magnitude of the association was similar in patients with ASCVD (NT-proBNP: aHR, 1.60; 95% CI, 1.45-1.77; hsTnT: aHR, 1.62; 95% CI, 1.45-1.81) and multiple risk factors for ASCVD (NT-proBNP: aHR, 1.62; 95% CI, 1.40-1.88; hsTnT: aHR, 1.51; 95% CI, 1.29-1.77). Moreover, both biomarkers remained independently associated with MACE when both were included in the multivariable model (NT-proBNP: aHR, 1.46; 95% CI, 1.34-1.60; hsTnT: aHR, 1.39; 95% CI, 1.26-1.53). Modeled as a continuous variable, baseline biomarker levels did not modify the relative treatment effect of dapagliflozin vs placebo with MACE. However, the relative risk reduction numerically grew with higher biomarker levels, as did the baseline risk. Thus, MACE event rates were nominally lower in dapagliflozin-treated vs placebo-treated patients with biomarker concentrations in the top quartile (NT-proBNP: HR, 0.83; 95% CI, 0.71-0.97; absolute risk reduction [ARR], 2.4%; hsTnT: HR, 0.85; 95% CI, 0.72-0.99; ARR, 2.7%), whereas there was no significant treatment effect in patients with biomarkers levels in quartiles 1 to 3 (NT-proBNP: HR, 1.02; 95% CI, 0.88-1.18; ARR, 0%; hsTnT: HR, 0.97; 95% CI, 0.84-1.13; ARR, 0.2%). CONCLUSIONS AND RELEVANCE: In this study, NT-proBNP and hsTnT levels were associated with the risk for future cardiovascular events in both primary and secondary prevention patients with T2D. Both cardiac biomarkers were helpful to identify patients at very high risk for atherosclerotic events that may derive reduction in risk of MACE with dapagliflozin. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01730534
- Published
- 2023
- Full Text
- View/download PDF
10. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
- Author
-
Nadarajah, Ramesh, Ludman, Peter, Appelman, Yolande, Brugaletta, Salvatore, Budaj, Andrzej, Bueno, Hector, Huber, Kurt, Kunadian, Vijay, Leonardi, Sergio, Lettino, Maddalena, Milasinovic, Dejan, and Gale, Chris P
- Published
- 2023
- Full Text
- View/download PDF
11. Acidic urine as a novel risk factor for diuretic resistance and worse in-hospital prognosis in patients with acute heart failure.
- Author
-
Imiela, Tomasz, Imiela, Anna M., Karczmarewicz, Grzegorz, and Budaj, Andrzej
- Published
- 2021
- Full Text
- View/download PDF
12. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial
- Author
-
Batra, Gorav, Renlund, Henrik, Kunadian, Vijay, James, Stefan K, Storey, Robert F, Steg, P Gabriel, Katus, Hugo A, Harrington, Robert A, Gibson, C Michael, Budaj, Andrzej, Siegbahn, Agneta, and Wallentin, Lars
- Abstract
Graphical Abstract
- Published
- 2022
- Full Text
- View/download PDF
13. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome
- Author
-
Batra, Gorav, Ghukasyan Lakic, Tatevik, Lindbäck, Johan, Held, Claes, White, Harvey D., Stewart, Ralph A. H., Koenig, Wolfgang, Cannon, Christopher P., Budaj, Andrzej, Hagström, Emil, Siegbahn, Agneta, and Wallentin, Lars
- Abstract
IMPORTANCE: Inflammation promotes cardiovascular disease and anti-inflammatory treatment reduces cardiovascular events in patients with chronic coronary syndrome. Chronic kidney disease (CKD) is a risk factor for cardiovascular disease. It is unclear how inflammation mediated by interleukin 6 (IL-6) in patients with CKD is linked to cardiovascular disease. OBJECTIVE: To investigate associations between IL-6 and cardiovascular outcomes in patients with chronic coronary syndrome in association with kidney function. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients enrolled at 663 centers in 39 countries with chronic coronary syndrome who were included in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial. Patients were enrolled between December 2008 and April 2010 and were followed up for a median length of 3.7 years. Analysis in this substudy began September 2020. EXPOSURES: Exposures were IL-6 and creatinine estimated glomerular filtration rates (eGFR), which were collected at baseline. Associations between continuous and categorical levels (<2.0 ng/L vs ≥2.0 ng/L) of IL-6 and cardiovascular outcomes were tested in association with eGFR cutoffs (normal eGFR level [≥90 mL/min/1.73 m2], mildly decreased eGFR level [60-90 mL/min/1.73 m2], and moderately to severely decreased eGFR level [<60 mL/min/1.73 m2]). MAIN OUTCOMES AND MEASURES: Main outcome was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, and stroke. RESULTS: This substudy of the STABILITY trial included 14 611 patients with available IL-6 levels at baseline. The median (interquartile range) age was 65 (59-71) years, and 2700 (18.5%) were female. During follow-up, MACE occurred in 1459 individuals (10.0%). Higher levels of IL-6 were in continuous models independently associated with risk of MACE (P < .001) in all CKD strata. Using predefined strata, elevated IL-6 level (≥2.0 vs <2.0 ng/L) was associated with increased risk of MACE at normal kidney function (2.9% vs 1.9% events/y [hazard ratio, 1.35; 95% CI, 1.02-1.78]), mild CKD (3.3% vs 1.9% [hazard ratio, 1.57; 95% CI, 1.35-1.83]), and moderate to severe CKD (5.0% vs 2.9% [hazard ratio, 1.60; 95% CI, 1.28-1.99]). CONCLUSIONS AND RELEVANCE: In patients with chronic coronary syndrome, elevated levels of IL-6 were associated with risk of MACE in all CKD strata. Thus, IL-6 and CKD stage may help when identifying patients with chronic coronary syndrome for anti-inflammatory treatment.
- Published
- 2021
- Full Text
- View/download PDF
14. Risk markers of incident atrial fibrillation in patients with coronary heart disease.
- Author
-
Tomasdottir MD, Maria, Held, Claes, Hadziosmanovic, Nermin, Westerbergh, Johan, Lindbäck, Johan, Aylward, Philip E., Budaj, Andrzej, Cannon, Christopher P., Engdahl, Johan, Granger, Christopher B., Koenig, Wolfgang, Manolis, Athanasios J., Oldgren, Jonas, Stewart, Ralph A.H., Svennberg, Emma, Vinereanu, Dragos, White, Harvey D., Siegbahn, Agneta, Wallentin, Lars, and Hijazi, Ziad
- Abstract
Background: In patients with coronary heart disease (CHD), atrial fibrillation (AF) is associated with increased morbidity and mortality. We investigated the associations between clinical risk factors and biomarkers with incident AF in patients with CHD.Methods and Results: Around 13,153 patients with optimally treated CHD included in the STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) trial with plasma samples obtained at randomization. Mean follow-up time was 3.5 years. The association between clinical risk factors and biomarkers with incident AF was estimated with Cox-regression models. Validation was performed in 1,894 patients with non-ST-elevation acute coronary syndrome included in the FRISC-II trial. The median (min-max) age was 64 years (range 26-92) and 2,514 (19.1%) were women. A total of 541 patients, annual incidence rate of 1.2%, developed AF during follow-up. In multivariable models, older age, higher levels of NT-proBNP, higher body mass index (BMI), male sex, geographic regions, low physical activity, and heart failure were independently associated with increased risk of incident AF with hazard ratios ranging from 1.04 to 1.79 (P ≤ .05). NT-proBNP improved the C-index from 0.70 to 0.71. In the validation cohort, age, BMI, and NT-proBNP were associated with increased risk of incident AF with similar hazard ratios.Conclusions: In patients with optimally treated CHD, the incidence of new AF was 1.2% per year. Age, NT-proBNP as a marker of impaired cardiac function, and BMI were the strongest factors, independently and consistently associated with incident AF. Male sex and low physical activity may also contribute to the risk of AF in patients with CHD. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. Smoker's paradox: controversy remains.
- Author
-
Ramotowski, Bogumił and Budaj, Andrzej
- Published
- 2023
- Full Text
- View/download PDF
16. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.
- Author
-
Joseph, Philip, Dokainish, Hisham, McCready, Tara, Budaj, Andrzej, Roy, Ambuj, Ertl, Georg, Gomez-Mesa, Juan Esteban, Leong, Darryl, Ezekowitz, Justin, Hage, Camilla, Lanas, Fernando, Maggioni, Aldo P., Sliwa, Karen, Zhu, Jun, Rouleau, Jean, Balasubramanian, Kumar, Yusuf, Salim, and G-CHF Investigators
- Abstract
The goal of the global congestive heart failure (G-CHF) registry is to collect comparative international data on heart failure characteristics, management, and outcomes and to better understand the determinants that impact the clinical course of heart failure. METHODS: G-CHF is a multicenter, prospective cohort study of adult patients with a new or prior clinical diagnosis of heart failure. We have enrolled 23,047 participants from 257 centers in 40 countries from 8 major geographic regions of the world, with recruitment ongoing. Approximately 4,000 participants will also participate in substudies to assess frailty, comorbidity, diet, barriers to care, biomarkers, and planned detailed echocardiographic analyses. Follow-up is planned for a period of 5 years. The primary outcome is cause-specific mortality. Key secondary outcomes include hospitalizations, quality of life, and major cardiovascular and noncardiovascular outcomes. A total of 31.9% of participants were enrolled as inpatients. Thus far, mean age of the cohort at baseline is 63.1 years, and 60.8% are male. Participants most commonly have heart failure with reduced ejection fraction (53.6%) followed by preserved ejection fraction (24.2%) and midrange ejection fraction (20.6%). The most common causes of heart failure are ischemic (37.8%) followed by hypertensive (20.0%), idiopathic (15.1%), and valvular disease (8.8%). CONCLUSION: G-CHF will provide a greater understanding of the characteristics of the global heart failure population, variations in its management, clinical outcomes, and what continues to impact morbidity and mortality in this high-risk population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
- Author
-
White, Harvey D., Stewart, Ralph A.H., Dalby, Anthony J., Stebbins, Amanda, Cannon, Christopher P., Budaj, Andrzej, Linhart, Ales, Pais, Prem, Diaz, Rafael, Steg, Philippe Gabriel, Krug-Gourley, Sue, Granger, Christopher B., Hochman, Judith S., Koenig, Wolfgang, Harrington, Robert A., Held, Claes, Wallentin, Lars, and STABILITY Investigators
- Abstract
Background: In patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE): cardiovascular death, myocardial infarction, and stroke.Methods: EBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) <140/90 mm Hg and low-density lipoprotein-cholesterol (LDL-C) <100 mg/dL and <70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c) < 7% and BP of <130/80 mm Hg were recommended. Feedback to investigators about rates of EBM and SOC was provided regularly.Results: In 13,623 patients, 1-year landmark analysis assessed the association between EBM, SOC targets, and MACE during follow-up of 2.7 years (median) after adjustment in a Cox proportional hazards model. At 1 year, aspirin was prescribed in 92.5% of patients, statins in 97.2%, β-blockers in 79.0%, and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in 76.9%. MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) compared with LDL-C ≥ 100 mg/dL (hazard ratio [HR] 0.694, 95% CI 0.594-0.811) and lower with LDL-C < 70 mg/dL compared with LDL-C < 100 mg/dL (70-99 mg/dL) (HR 0.834, 95% CI 0.708-0.983). MACE was lower with HbA1c < 7% compared with HbA1c ≥ 7% (HR 0.705, 95% CI 0.573-0.866). There was no effect of BP targets on MACE.Conclusions: MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) and even lower with LDL-C < 70 mg/dL. MACE in patients with diabetes was lower with HbA1c < 7%. Achievement of targets is associated with improved patient outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
18. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- Author
-
Ray, Kausik K, Colhoun, Helen M, Szarek, Michael, Baccara-Dinet, Marie, Bhatt, Deepak L, Bittner, Vera A, Budaj, Andrzej J, Diaz, Rafael, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J Wouter, Loizeau, Virginie, Lopes, Renato D, Moryusef, Angèle, Murin, Jan, Pordy, Robert, Ristic, Arsen D, Roe, Matthew T, Tuñón, José, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G, Steg, Philippe Gabriel, Schwartz, Gregory G., Steg, Ph. Gabriel, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Szarek, Michael, White, Harvey D., Zeiher, Andreas M., Tricoci, Pierluigi, Roe, Matthew T., Mahaffey, Kenneth W., Edelberg, Jay M., Hanotin, Corinne, Lecorps, Guillaume, Moryusef, Angèle, Pordy, Robert, Sasiela, William J., Tamby, Jean-François, Aylward, Philip E., Drexel, Heinz, Sinnaeve, Peter, Dilic, Mirza, Lopes, Renato D., Gotcheva, Nina N., Prieto, Juan-Carlos, Yong, Huo, López-Jaramillo, Patricio, Pećin, Ivan, Reiner, Zeljko, Ostadal, Petr, Viigimaa, Margus, Nieminen, Markku S., Chumburidze, Vakhtang, Marx, Nikolaus, Danchin, Nicolas, Liberopoulos, Evangelos, Montenegro Valdovinos, Pablo Carlos, Tse, Hung-Fat, Kiss, Robert Gabor, Xavier, Denis, Zahger, Doron, Valgimigli, Marco, Kimura, Takeshi, Kim, Hyo Soo, Kim, Sang-Hyun, Erglis, Andrejs, Laucevicius, Aleksandras, Kedev, Sasko, Yusoff, Khalid, Ramos López, Gabriel Arturo, Alings, Marco, Halvorsen, Sigrun, Correa Flores, Roger M., Budaj, Andrzej, Morais, Joao, Dorobantu, Maria, Karpov, Yuri, Ristic, Arsen D., Chua, Terrance, Murin, Jan, Fras, Zlatko, Dalby, Anthony J., Tuñón, José, de Silva, H. Asita, Hagström, Emil, Landmesser, Ulf, Chiang, Chern-En, Sritara, Piyamitr, Guneri, Sema, Parkhomenko, Alexander, Ray, Kausik K., Moriarty, Patrick M., Vogel, Robert, Chaitman, Bernard, Kelsey, Sheryl F., Olsson, Anders G., Rouleau, Jean-Lucien, Simoons, Maarten L., Alexander, Karen, Meloni, Chiara, Rosenson, Robert, Sijbrands, Eric J.G., Tricoci, Pierluigi, Alexander, John H., Armaganijan, Luciana, Bagai, Akshay, Bahit, Maria Cecilia, Brennan, J. Matthew, Clifton, Shaun, DeVore, Adam D., Deloatch, Shalonda, Dickey, Sheila, Dombrowski, Keith, Ducrocq, Grégory, Eapen, Zubin, Endsley, Patricia, Eppinger, Arleen, Harrison, Robert W., Hess, Connie Ng, Hlatky, Mark A., Jordan, Joseph Dedrick, Knowles, Joshua W., Kolls, Bradley J., Kong, David F., Leonardi, Sergio, Lillis, Linda, Maron, David J., Marcus, Jill, Mathews, Robin, Mehta, Rajendra H., Mentz, Robert J., Moreira, Humberto Graner, Patel, Chetan B., Bernardez-Pereira, Sabrina, Perkins, Lynn, Povsic, Thomas J., Puymirat, Etienne, Schuyler Jones, William, Shah, Bimal R., Sherwood, Matthew W., Stringfellow, Kenya, Sujjavanich, Darin, Toma, Mustafa, Trotter, Charlene, Van Diepen, Sean, Wilson, Matthew D., Yan, Andrew T., Schiavi, Lilia B., Garrido, Marcelo, Alvarisqueta, Andrés F., Sassone, Sonia A., Bordonava, Anselmo P., Alves De Lima, Alberto E., Schmidberg, Jorge M., Duronto, Ernesto A., Caruso, Orlando C., Novaretto, Leonardo P., Hominal, Miguel Angel, Montaña, Oscar R., Caccavo, Alberto, Gomez Vilamajo, Oscar A., Lorenzatti, Alberto J., Cartasegna, Luis R., Paterlini, Gustavo A., Mackinnon, Ignacio J., Caime, Guillermo D., Amuchastegui, Marcos, Salomone, Oscar, Codutti, Oscar R., Jure, Horacio O., Bono, Julio OE, Hrabar, Adrian D., Vallejos, Julio A., Ahuad Guerrero, Rodolfo A., Novoa, Federico, Patocchi, Cristian A., Zaidman, Cesar J., Giuliano, Maria E., Dran, Ricardo D., Vico, Marisa L., Carnero, Gabriela S., Guzman, Pablo N., Medrano Allende, Juan C., Garcia Brasca, Daniela F., Bustamante Labarta, Miguel H, Nani, Sebastian, Blumberg, Eduardo DS, Colombo, Hugo R, Liberman, Alberto, Fuentealba, Victorino, Luciardi, Hector L, Waisman, Gabriel D, Berli, Mario A, Garcia Duran, Ruben O, Cestari, Horacio G, Luquez, Hugo A, Giordano, Jorge A, Saavedra, Silvia S, Zapata, Gerardo, Costamagna, Osvaldo, Llois, Susana, Waites, Jonathon H, Collins, Nicholas, Soward, Allan, Hii, Chris LS, Shaw, James, Arstall, Margaret A, Horowitz, John, Ninio, Daniel, Rogers, James F, Colquhoun, David, Oqueli Flores, Romulo E, Roberts-Thomson, Philip, Raffel, Owen, Lehman, Sam J, Aroney, Constantine, Coverdale, Steven GM, Garrahy, Paul J, Starmer, Gregory, Sader, Mark, Carroll, Patrick A, Dick, Ronald, Zweiker, Robert, Hoppe, Uta, Huber, Kurt, Berger, Rudolf, Delle-Karth, Georg, Frey, Bernhard, Weidinger, Franz, Faes, Dirk, Hermans, Kurt, Pirenne, Bruno, Leone, Attilio, Hoffer, Etienne, Vrolix, Mathias CM, De Wolf, Luc, Wollaert, Bart, Castadot, Marc, Dujardin, Karl, Beauloye, Christophe, Vervoort, Geert, Striekwold, Harry, Convens, Carl, Roosen, John, Barbato, Emanuele, Claeys, Marc, Cools, Frank, Terzic, Ibrahim, Barakovic, Fahir, Midzic, Zlatko, Pojskic, Belma, Fazlibegovic, Emir, Kulić, Mehmed, Durak-Nalbantic, Azra, Vulic, Dusko, Muslibegovic, Adis, Goronja, Boris, Reis, Gilmar, Sousa, Luciano, Nicolau, Jose C, Giorgeto, Flavio E, Silva, Ricardo P, Nigro Maia, Lilia, Rech, Rafael, Rossi, Paulo RF, Cerqueira, Maria José AG, Duda, Norberto, Kalil, Renato, Kormann, Adrian, Abrantes, José Antonio M, Pimentel Filho, Pedro, Soggia, Ana Priscila, de Santos, Mayler ON, Neuenschwander, Fernando, Bodanese, Luiz C, Michalaros, Yorghos L, Eliaschewitz, Freddy G, Vidotti, Maria H, Leaes, Paulo E, Botelho, Roberto V, Kaiser, Sergio, Manenti, Euler Roberto Fernandes, Precoma, Dalton B, Moura Jorge, Jose C, de B Silva, Pedro G, Silveira, Jose A, Saporito, Wladmir, Marin-Neto, Jose A, Feitosa, Gilson S, Ritt, Luiz Eduardo F, de Souza, Juliana A, Costa, Fernando, Souza, Weimar KSB, Reis, Helder JL, Machado, Leandro, Ayoub, José Carlos Aidar, Todorov, Georgi V, Nikolov, Fedya P, Velcheva, Elena S, Tzekova, Maria L, Benov, Haralambi O, Petranov, Stanislav L, Tumbev, Haralin S, Shehova-Yankova, Nina S, Markov, Dimitar T, Raev, Dimitar H, Mollov, Mihail N, Kichukov, Kostadin N, Ilieva-Pandeva, Katya A, Ivanova, Raya, Gospodinov, Maryana, Mincheva, Valentina M, Lazov, Petar V, Dimov, Bojidar I, Senaratne, Manohara, Stone, James, Kornder, Jan, Pearce, Stephen, Dion, Danielle, Savard, Daniel, Pesant, Yves, Pandey, Amritanshu, Robinson, Simon, Gosselin, Gilbert, Vizel, Saul, Hoag, Gordon, Bourgeois, Ronald, Morisset, Anne, Sabbah, Eric, Sussex, Bruce, Kouz, Simon, MacDonald, Paul, Diaz, Ariel, Michaud, Nicolas, Fell, David, Leung, Raymond, Vuurmans, Tycho, Lai, Christopher, Nigro, Frank, Davies, Richard, Nogareda, Gustavo, Vijayaraghavan, Ram, Ducas, John, Lepage, Serge, Mehta, Shamir, Cha, James, Dupuis, Robert, Fong, Peter, Lutchmedial, Sohrab, Rodes-Cabau, Josep, Fadlallah, Hussein, Cleveland, David, Huynh, Thao, Bata, Iqbal, Hameed, Adnan, Pincetti, Cristian, Potthoff, Sergio, Prieto, Juan C, Acevedo, Monica, Aguirre, Arnoldo, Vejar, Margarita, Yañez, Mario, Araneda, Guillermo, Fernandez, Mauricio, Perez, Luis, Varleta, Paola, Florenzano, Fernando, Huidobro, Laura, Raffo, Carlos A, Olivares, Claudia, Nahuelpan, Leonardo, Montecinos, Humberto, Chen, Jiyan, Dong, Yugang, Huang, Weijian, Wang, Jianzhong, Huang, Shi'An, Yao, Zhuhua, Li, Xiang, Cui, Lan, Lin, Wenhua, Sun, Yuemin, Wang, Jingfeng, Li, Jianping, Zhang, Xuelian, Zhu, Hong, Chen, Dandan, Huang, Lan, Dong, Shaohong, Su, Guohai, Xu, Biao, Su, Xi, Cheng, Xiaoshu, Lin, Jinxiu, Zong, Wenxia, Li, Huanming, Feng, Yi, Xu, Dingli, Yang, Xinchun, Ke, Yuannan, Lin, Xuefeng, Zhang, Zheng, Zheng, Zeqi, Luo, Zhurong, Chen, Yundai, Ding, Chunhua, Zhong, Yi, Zheng, Yang, Li, Xiaodong, Peng, Daoquan, Zhao, Shuiping, Li, Ying, Liu, Xuebo, Wei, Meng, Liu, Shaowen, Yu, Yihua, Qu, Baiming, Jiang, Weihong, Zhou, Yujie, Zhao, Xingsheng, Yuan, Zuyi, Guo, Ying, Xu, Xiping, Shi, Xubo, Ge, Junbo, Fu, Guosheng, Bai, Feng, Fang, Weiyi, Shou, Xiling, Yang, Xiangjun, Wang, Jian'An, Xiang, Meixiang, Sun, Yingxian, Lu, Qinghua, Zhang, Ruiyan, Zhu, Jianhua, Xu, Yizhou, Fan, Zhongcai, Li, Tianchang, Wu, Chun, Jaramillo, Nicolas, Sanchez Vallejo, Gregorio, Luna Botia, Diana C, Botero Lopez, Rodrigo, Molina De Salazar, Dora I, Cadena Bonfanti, Alberto J, Cotes Aroca, Carlos, Diego Higuera, Juan, Blanquicett, Marco, Barrera Silva, Sandra I, Garcia Lozada, Henry J, Coronel Arroyo, Julian A, Accini Mendoza, Jose L, Fernandez Ruiz, Ricardo L, Quintero Ossa, Alvaro M., Manzur Jatin, Fernando G, Sotomayor Herazo, Aristides, Castellanos Parada, Jeffrey, Suarez Arambula, Rafael, Urina Triana, Miguel A, Fernandez Trujillo, Angela M, Strozzi, Maja, Car, Siniša, Jerić, Melita, Miličić, Davor, Benčić, Martina Lovrić, Pintarić, Hrvoje, Prvulović, Đeiti, Šikić, Jozica, Peršić, Viktor, Mileta, Dean, Štambuk, Kresimir, Babić, Zdravko, Tomulic, Vjekoslav, Lukenda, Josip, Mejic-Krstulovic, Stanka, Starcevic, Boris, Spinar, Jindrich, Horak, David, Velicka, Zdenek, Stasek, Josef, Alan, David, Machova, Vilma, Linhart, Ales, Novotny, Vojtech, Kaucak, Vladimir, Rokyta, Richard, Naplava, Robert, Coufal, Zdenek, Adamkova, Vera, Podpera, Ivo, Zizka, Jiri, Motovska, Zuzana, Marusincova, Ivana, Svab, Premysl, Heinc, Petr, Kuchar, Jiri, Povolny, Petr, Matuska, Jiri, Poulsen, Steen H, Raungaard, Bent, Clemmensen, Peter, Bang, Lia E, May, Ole, Bøttcher, Morten, Hove, Jens D, Frost, Lars, Gislason, Gunnar, Larsen, John, Betton Johansen, Peter, Hald, Flemming, Johansen, Peter, Jeppesen, Jørgen, Nielsen, Tonny, Kristensen, Kjeld S, Walichiewicz, Piotr Maria, Lomholdt, Jens D, Klausen, Ib C, Nielsen, Peter Kaiser, Davidsen, Flemming, Videbaek, Lars, Soots, Mai, Vahula, Veiko, Hedman, Anu, Soopõld, Üllar, Märtsin, Kaja, Jurgenson, Tiina, Kristjan, Arved, Helsinki, Juhani K, Vikman, Saila, Huikuri, Heikki, Airaksinen, Juhani, Coste, Pierre, Ferrari, Emile, Morel, Olivier, Montalescot, Gilles, Machecourt, Jacques, Barone-Rochette, Gilles, Mansourati, Jacques, Cottin, Yves, Leclercq, Florence, Belhassane, Abdelkader, Delarche, Nicolas, Boccara, Franck, Paganelli, Franck, Clerc, Jérôme, Schiele, Francois, Aboyans, Victor, Probst, Vincent, Berland, Jacques, Lefèvre, Thierry, Citron, Bernard, Khintibidze, Irakli, Shaburishvili, Tamaz, Pagava, Zurab, Ghlonti, Ramaz, Lominadze, Zaza, Khabeishvili, George, Hemetsberger, Rayyan, Edward, Kemala, Rauch-Kröhnert, Ursula, Stratmann, Matthias, Appel, Karl-Friedrich, Schmidt, Ekkehard, Omran, Heyder, Stellbrink, Christoph, Dorsel, Thomas, Lianopoulos, Emmanouil, Vöhringer, Hans Friedrich, Marx, Roger, Zirlik, Andreas, Schellenberg, Detlev, Heitzer, Thomas, Laufs, Ulrich, Werner, Christian, Marx, Nikolaus, Gielen, Stephan, Nuding, Sebastian, Winkelmann, Bernhard, Behrens, Steffen, Sydow, Karsten, Karakas, Mahir, Simonis, Gregor, Muenzel, Thomas, Werner, Nikos, Leggewie, Stefan, Böcker, Dirk, Braun-Dullaeus, Rüdiger, Toursarkissian, Nicole, Jeserich, Michael, Weißbrodt, Matthias, Schaeufele, Tim, Weil, Joachim, Völler, Heinz, Waltenberger, Johannes, Natour, Mohammed, Schmitt, Susanne, Müller-Wieland, Dirk, Steiner, Stephan, Heidenreich, Lothar, Offers, Elmar, Gremmler, Uwe, Killat, Holger, Rieker, Werner, Patsilinakos, Sotiris, Kartalis, Athanasios, Manolis, Athanassios, Sionis, Dimitrios, Chachalis, Geargios, Skoumas, Ioannis, Athyros, Vasilios, Vardas, Panagiotis, Parthenakis, Frangkiskos, Alexopoulos, Dimitrios, Hahalis, Georgios, Lekakis, John, Hatzitolios, Apostolos, Fausto Ovando, Sergio R, Arango Benecke, Juan L, Rodriguez De Leon, Edgar R, Yan, Bryan PY, Siu, David CW, Turi, Tibor, Merkely, Bela, Ungi, Imre, Lupkovics, Geza, Nagy, Lajos, Katona, András, Édes, István, Müller, Gábor, Horvath, Iván, Kapin, Tibor, Szigeti, Zsolt, Faluközy, József, Kumbla, Mukund, Sandhu, Manjinder, Annam, Sharath, Proddutur, Naveen Reddy, Regella, Reddy, Premchand, Rajendra K, Mahajan, Ajaykumar, Pawar, Sudhir, Abhyanakar, Atul D, Kerkar, Prafulla, Govinda, Ravishankar A, Oomman, Abraham, Sinha, Dhurjati, Patil, Sachin N, Kahali, Dhiman, Sawhney, Jitendra, Joshi, Abhijeet B, Chaudhary, Sanjeev, Harkut, Pankaj, Guha, Santanu, Porwal, Sanjay, Jujjuru, Srimannarayana, Pothineni, Ramesh B, Monteiro, Minguel R, Khan, Aziz, Iyengar, Shamanna S, Grewal, Jasprakash Singh, Chopda, Manoj, Fulwani, Mahesh C, Patange, Aparna, Sachin, Patil, Chopra, Vijay K, Goyal, Naresh K, Shinde, Rituparna, Manakshe, Gajendra V, Patki, Nitin, Sethi, Sumeet, Munusamy, Vengatesh, Karna, Sunil, Thanvi, Sunil, Adhyapak, Srilakshmi, Patil, Chandrakant, Pandurangi, Ulhas, Mathur, Rishabh, Gupta, Jugal, Kalashetti, Suhas, Bhagwat, Ajit, Raghuraman, Bagirath, Yerra, Shiv Kumar, Bhansali, Prasant, Borse, Rohidas, Rahul, Patil, Das, Srihari, Kumar, Vinay, Abdullakutty, Jabir, Saathe, Shireesh, Palimkar, Priya, Sathe, Shireesh, Atar, Shaul, Shechter, Michael, Mosseri, Morris, Arbel, Yaron, Ehud, Chorin, Ofer, Havakuk, Lotan, Chaim, Rosenschein, Uri, Katz, Amos, Henkin, Yaakov, Francis, Adi, Klutstein, Marc, Nikolsky, Eugenia, Zukermann, Robert, Turgeman, Yoav, Halabi, Majdi, Marmor, Alon, Kornowski, Ran, Jonas, Michael, Amir, Offer, Hasin, Yonathan, Rozenman, Yoseph, Fuchs, Shmuel, Zvi, Vered, Hussein, Osamah, Gavish, Dov, Vered, Zvi, Caraco, Yoseph, Elias, Mazen, Tov, Naveh, Wolfovitz, Efrat, Lishner, Michael, Elias, Nizar, Piovaccari, Giancarlo, De Pellegrin, Annamaria, Garbelotto, Raffaella, Guardigli, Gabriele, Marco, Valgimigli, Licciardello, Giovanni, Auguadro, Carla, Scalise, Filippo, Cuccia, Claudio, Salvioni, Alessandro, Musumeci, Giuseppe, Senni, Michelle, Calabrò, Paolo, Novo, Salvatore, Faggiano, Pompilio, Metra, Marco, De Cesare, Nicoletta B, Berti, Sergio, Cavallini, Claudio, Puccioni, Enrico, Galvani, Marcello, Tespili, Maurizio, Piatti, Piermarco, Palvarini, Michela, De Luca, Giuseppe, Violini, Roberto, De Leo, Alessandro, Olivari, Zoran, Perrone Filardi, Pasquale, Ferratini, Maurizio, Racca, Vittorio, Dai, Kazuoki, Shimatani, Yuji, Kamiya, Haruo, Ando, Kenji, Takeda, Yoshihiro, Morino, Yoshihiro, Hata, Yoshiki, Kimura, Kazuo, Kishi, Koichi, Michishita, Ichiro, Uehara, Hiroki, Higashikata, Toshinori, Hirayama, Atsushi, Hirooka, Keiji, Doi, Yasuji, Sakagami, Satoru, Taguchi, Shuichi, Koike, Akihiro, Fujinaga, Hiroyuki, Koba, Shinji, Kozuma, Ken, Kawasaki, Tomohiro, Ono, Yujiro, Shimizu, Masatoshi, Katsuda, Yousuke, Wada, Atsuyuki, Shinke, Toshiro, Kimura, Takeshi, Ako, Junya, Fujii, Kenshi, Takahashi, Toshiyuki, Sakamoto, Tomohiro, Nakao, Koichi, Furukawa, Yutaka, Sugino, Hiroshi, Tamura, Ritsu, Mano, Toshiaki, Uematsu, Masaaki, Utsu, Noriaki, Ito, Kashima, Haraguchi, Takuya, Sato, Katsuhiko, Ueda, Yasunori, Nishibe, Akira, Fujimoto, Kazuteru, Masutani, Motomaru, Yoon, Jung Han, Kim, Hack-Lyoung, Park, Hun Sik, Chae, In-Ho, Kim, Moo Hyun, Jeong, Myung Ho, Rha, Seungwoon, Kim, Chongjin, Kim, Hyo-Soo, Kim, Hae Young, Hong, Taekjong, Tahk, Seung-Jea, Kim, Youngkwon, Busmane, Arija, Pontaga, Natalija, Strelnieks, Aldis, Mintale, Iveta, Sime, Iveta, Petrulioniene, Zaneta, Kavaliauskiene, Roma, Jurgaitiene, Ruta, Sakalyte, Gintare, Slapikas, Rimvydas, Norkiene, Sigute, Misonis, Nerijus, Kibarskis, Aleksandras, Kubilius, Raimondas, Bojovski, Stojko, Lozance, Nensi, Kjovkaroski, Aleksandar, Doncovska, Snezana, Ong, Tiong Kiam, Kasim, Sazzli, Maskon, Oteh, Kandasamy, Balachandran, Liew, Houng B, Wan Mohamed, Wan Mohd Izani, García Castillo, Armando, Carrillo Calvillo, Jorge, Fajardo Campos, Pedro, Núñez Fragoso, Juan Carlos, Bayram Llamas, Edmundo Alfredo, Alcocer Gamba, Marco Antonio, Carranza Madrigal, Jaime, González Salas, Luis Gerardo, López Rosas, Enrique, González Díaz, Belinda, Salcido Vázquez, Eduardo, Nacoud Ackar, Alfredo, Llamas Esperón, Guillermo Antonio, Martínez Sánchez, Carlos Rodolfo, Guerrero De Leon, María, Suarez Otero, Rodrigo, Fanghänel Salmón, Guillermo, Pérez Ríos, Jesús Antonio, Garza Ruíz, José Angel, Breedveld, Robert W, Feenema-Aardema, Margriet, Borger-Van Der Burg, Alida, Hoogslag, Pieter AM, Suryapranata, Harry, Oomen, Antonius, Van Haelst, Paulus, Wiersma, Jacobijne J, Basart, Dirk, Van Der Wal, Ruud MA, Zwart, Peter, Monraats, Pascalle, Van Kesteren, Henricus, Karalis, Ioannis, Jukema, Johan, Verdel, Gerardus JE, Brueren, Bart RG, Troquay, Roland PTh, Viergever, Eric P, Al-Windy, Nadea YY, Bartels, Gerard L, Cornel, Jan H, Hermans, Walter RM, Herrman, Johannes PR, Bos, Robert J, Groutars, Reginald GEJ, Van Der Zwaan, Coenraad C, Kaplan, Refik, Lionarons, Raymond, Ronner, Eelko, Groenemeijer, Bjorn E, Bronzwaer, Patrick NA, Liem, Anho AH, Rensing, Bernard JWM, Bokern, Marcel JJA, Nijmeijer, Remco, Hersbach, Ferry MRJ, Willems, Frank F, Gosselink, Antonius TM, Rasoul, Saman, Elliott, John, Wilkins, Gerard, Fisher, Raewyn, Scott, Douglas, Hart, Hamish, Stewart, Ralph, Harding, Scott, Ternouth, Ian, Fisher, Nicholas, Wilson, Samuel, Aitken, Denise, Anscombe, Russell, Davidson, Laura, Tomala, Tadeusz, Nygård, Ottar, Sparby, Jon Arne, Andersen, Kjell, Gullestad, Lars, Jortveit, Jarle, Munk, Peter S, Singsaas, Erlend gyllensten, Hurtig, Ulf, Calderon Ticona, Jorge R, Durand Velasquez, Julio R, Negron Miguel, Sandra A, Sanabria Perez, Enrique S, Carrion Chambilla, Jesus M, Chavez Ayala, Carlos A, Castillo Leon, Reynaldo P, Vargas Gonzales, Rolando J, Hernandez Zuniga, Jose D, Camacho Cosavalente, Luis A, Bravo Mannucci, Jorge E, Heredia Landeo, Javier, Llerena Navarro, Nassip C, Roldan Concha, Yudy M, Rodriguez Chavez, Víctor E, Anchante Hernandez, Henry A, Zea Nunez, Carlos A, Mogrovejo Ramos, Walter, Ferrolino, Arthur, Sy, Rosa Allyn G, Tirador, Louie, Sy, Rody G, Matiga, Generoso, Coching, Raul Martin, Bernan, Alisa, Rogelio, Gregorio, Morales, Dante D., Tan, Edgar, Sulit, Dennis Jose, Wlodarczak, Adrian, Jaworska, Krystyna, Skonieczny, Grzegorz, Pawlowicz, Lidia, Wojewoda, Pawel, Busz-Papiez, Benita, Bednarski, Janusz, Goch, Aleksander, Staneta, Pawel, Dulak, Elzbieta, Saminski, Krzysztof, Krasowski, Wlodzimierz, Sudnik, Wanda, Zurakowski, Aleksander, Skorski, Marcin, Miklaszewicz, Beata, Kubica, Jacek, Andrzej Lipko, Jan, Kostarska-Srokosz, Edyta, Piepiorka, Marek, Drzewiecka, Anna, Stasiewski, Arkadiusz, Blicharski, Tomasz, Bystryk, Leszek, Szpajer, Michal, Korol, Marek, Czerski, Tomasz, Mirek-Bryniarska, Ewa, Gniot, Jacek, Lubinski, Andrzej, Gorny, Jerzy, Franek, Edward, Raczak, Grzegorz, Szwed, Hanna, Monteiro, Pedro, Mesquita Bastos, Jose, Pereira, Helder H, Martins, Dinis, Seixo, Filipe, Mendonça, Carlos, Botelho, Ana, Caetano, Francisca, Minescu, Bogdan, Istratoaie, Octavian, Tesloianu, Dan N, Cristian, Gabriel, Dumitrescu, Silviu, Podoleanu, Cristian GC, Constantinescu, Mircea CA, Bengus, Cristina M, Militaru, Constantin, Rosu, Doina, Parepa, Irinel R, Matei, Adrian V, Alexandru, Tom M, Malis, Mihaela, Coman, Ioan, Stanescu-Cioranu, Rodica, Dimulescu, Doina, Shvarts, Yury, Orlikova, Olga, Kobalava, Zhanna, Barbarash, Olga L, Markov, Valentin, Lyamina, Nadezhda, Gordienko, Alexander, Zrazhevsky, Konstantin, Vishnevsky, Alexander Y, Gurevich, Victor, Stryuk, Raisa, Lomakin, Nikita V, Bokarev, Igor, Khlevchuk, Tatiana, Shalaev, Sergey, Khaisheva, Larisa, Chizhov, Petr, Viktorova, Inna, Osokina, Natalya, Shchekotov, Vladimir, Akatova, Evgenia, Chumakova, Galina, Libov, Igor, Voevoda, Mikhail I, Tretyakova, Tatyana V, Baranov, Evgeny, Shustov, Sergey, Yakushin, Sergey, Gordeev, Ivan, Khasanov, Niiaz, Reshetko, Olga, Sotnikova, Tatiana, Molchanova, Olga, Nikolaev, Konstantin, Gapon, Liudmila, Baranova, Elena, Shogenov, Zaur, Kosmachova, Elena, Karpov, Yuriy, Povzun, Anton, Egorova, Liudmila, Tyrenko, Vadim V, Ivanov, Igor G, Ilya, Masterov, Kanorsky, Sergey, Simic, Dragan, Ivanovic, Nikola, Davidovic, Goran, Tasic, Nebojsa, Asanin, Milika R., Stojic, Stevo, Apostolovic, Svetlana R., Ilic, Stevan, Putnikovic Tosic, Biljana, Stankovic, Aleksandar, Arandjelovic, Aleksandra, Radovanovic, Slavica, Todic, Branislava, Balinovac, Jovan, Dincic, Dragan V., Seferovic, Petar, Karadzic, Ana, Dodic, Slobodan, Dimkovic, Sinisa, Jakimov, Tamara, Poh, Kian-Keong, Ong, Hean Yee, Tang I-Shing, Justin, Micko, Karol, Nociar, Jan, Pella, Daniel, Fulop, Peter, Hranai, Marian, Palka, Juraj, Mazur, Juraj, Majercák, Ivan, Dzupina, Andrej, Fazekas, František, Gonsorcik, Jozef, Bugan, Viliam, Selecky, Juraj, Kamensky, Gabriel, Strbova, Jaroslava, Smik, Rudolf, Dukat, Andrej, Žuran, Ivan, Poklukar, Janez, Černič Šuligoj, Nataša, Cevc, Matija, Cyster, Henry P, Ranjith, Naresh, Corbett, Clive, Bayat, Junaid, Makotoko, Ellen Makoali, du Toit Theron, Hendrik, Kapp, Ilse E, de V Basson, Matthys M, Lottering, Hanlie, Van Aswegen, Dina, Van Zyl, Louis J, Sebastian, Peter J, Pillay, Thayabran, Saaiman, Jan A, Commerford, Patrick J, Cassimjee, Soraya, Riaz, Garda, Ebrahim, Iftikhar O, Sarvan, Mahomed, Mynhardt, Joseph H, Reuter, Helmuth, Moodley, Rajendran, Vida, Manuel, Cequier Fillat, Angel R., Bodí Peris, Vicente, Fuentes Jimenez, Francisco, Marín, Francisco, Cruz Fernández, Jose M, Hidalgo Urbano, Rafael Jesus, Gil-Extremera, Blas, Toledo, Pablo, Worner Diz, Fernando, Garcia-Dorado, David, Iñiguez, Andres, Tuñón Fernández, José, Gonzalez-Juanatey, Jose R, Fernandez Portales, Javier, Civeira Murillo, Fernando, Matas Pericas, Laia, Zamorano, Jose Luis, De Mora Martin, Manuel, Bruguera Cortada, Jordi, Alonso Martin, Joaquin J, Serrano Antolin, Jose Maria, De Berrazueta Fernández, José R, Vázquez de Prada, José Antonio, Díaz Fernández, Jose Francisco, García Lledó, José Alberto, Cosín Sales, Juan, Botas Rodriguez, Javier, Gusi Tragant, Gabriel, Benedicto, Amparo, Gonzalez-Juanatey, Carlos, Camprubí Potau, Mercedes, Plaza Perez, Ignacio, De La Tassa, César Morís, Loma-Osorio Rincon, Pablo, Balaguer Recena, Javier, Escudier, Juan M, Payeras, Antonio Coca, Alonso Orcajo, Norberto, Valdivielso, Pedro, Constantine, Godwin, Haniffa, Ruvaiz, Tissera, Nirmali, Amarasekera, Stanley, Ponnamperuma, Chandrike, Fernando, Nimali, Fernando, Kaputella, Jayawardena, Jayanthimala, Wijeyasingam, Santharaj, Ranasinghe, Gotabhaya, Ekanayaka, Ruvan, Mendis, Sepalika, Senaratne, Vajira, Mayurathan, Gnanamoorthy, Sirisena, Thilak, Rajapaksha, Ajantha, Herath, Jagath I, Amarasena, Naomali, Berglund, Stefan, Rasmanis, Gundars, Vedin, Ola, Witt, Nils, Mourtzinis, Georgios, Nicol, Peter, Hansen, Ole, Romeo, Stefano, Agergaard Jensen, Steen, Torstensson, Ingemar, Ahremark, Ulf, Sundelin, Torbjörn, Moccetti, Tiziano, Müller, Christian, Mach, Francois, Binde, Ronald, Tsai, Wei-Chuan, Ueng, Kwo-Chang, Lai, Wen-Ter, Liu, Ming-En, Hwang, Juey-Jen, Yin, Wei-Hsian, Hsieh, I-Chang, Hsieh, Ming-Jer, Lin, Wei Hsiang, Kuo, Jen-Yuan, Huang, Tsuei-Yuan, Fang, Chih-Yuan, Kaewsuwanna, Pinij, Soonfuang, Wasant, Jintapakorn, Woravut, Sukonthasarn, Apichard, Wongpraparut, Nattawut, Sastravaha, Krisada, Sansanayudh, Nakarin, Kehasukcharoen, Wirash, Piyayotai, Dilok, Chotnoparatpat, Paiboon, Camsari, Ahmet, Kultursay, Hakan, Mutlu, Bulent, Ersanli, Murat, Demirtas, Mustafa, Kirma, Cevat, Ural, Ertan, Koldas, Lale, Karpenko, Oleksandr, Prokhorov, Alexander, Vakaluyk, Ihor, Myshanych, Halyna, Reshotko, Dmytro, Batushkin, Valeriy, Rudenko, Leonid, Kovalskyi, Ihor, Kushnir, Mykola, Tseluyko, Vira, Mostovoy, Yuriy, Stanislavchuk, Mykola, Kyiak, Yulian, Karpenko, Yuriy, Malynovsky, Yaroslav, Klantsa, Andriy, Kutniy, Oles, Amosova, Ekaterina, Tashchuk, Viktor, Leshchuk, Oleh, Rishko, Mykola, Kopytsya, Mykola, Yagensky, Andriy, Vatutin, Mykola, Bagriy, Andriy, Barna, Olga M, Ushakov, Olexiy, Dzyak, Georgiy, Goloborodko, Borys, Rudenko, Anatolii, Zheleznyy, Volodymyr, Trevelyan, Jasper, Zaman, Azfar, Lee, Kaeng, Moriarty, Andrew, Aggarwal, Rajesh K, Clifford, Piers, Wong, Yuk-Ki, Iqbal, Syed MR, Subkovas, Eduardas, Braganza, Denise, Sarkar, David, Storey, Robert, Griffiths, Huw, McClure, Sam, Muthusamy, Rangasamy, Smith, Simon, Kurian, John, Levy, Terry, Barr, Craig, Kadr, Honer, Gerber, Robert, Simaitis, Audrius, Soran, Handrean, Mathur, Anthony, Brodison, Adrian, Ayaz, Mohammad, Cheema, Muhammad, Oliver, Richard, Thackray, Simon, Mudawi, Telal, Rahman, Gohar, Sultan, Ayyaz, Sharman, David, Sprigings, David, Butler, Rob, Wilkinson, Peter, Lip, Gregory YH, Halcox, Julian, Gallagher, Sean, Ossei-Gerning, Nicholas, Vardi, Gil, Baldari, Duccio, Brabham, David, Treasure II, Charles, Dahl, Charles, Palmer, Bruce, Wiseman, Alan, Khan, Abul, Puri, Sanjeev, Mohart, Ann Elizabeth, Ince, Carlos, Flores, Enrique, Wright, Scott, Cheng, Shi-Chi, Rosenberg, Michael, Rogers, William, Kosinski, Edward, Forgosh, Les, Waltman, Jonathan, Khan, Misal, Shoukfeh, Mohammad, Dagher, Georges, Cambier, Patrick, Lieber, Ira, Kumar, Priya, East, Cara, Krichmar, Perry, Hasan, Mian, White, Lindsey, Knickelbine, Thomas, Haldis, Thomas, Gillespie, Eve, Amidon, Thomas, Suh, David, Arif, Imran, Abdallah, Mouhamad, Akhter, Faiq, Carlson, Eric, D'Urso, Michael, El-Ahdab, Fadi, Nelson, William, Moriarty, Katie, Harris, Barry, Cohen, Steven, Carter, Luther, Doty, Daniel, Sabatino, Kenneth, Haddad, Tariq, Malik, Amir, Rao, Sunder, Mulkay, Angel, Jovin, Ion, Klancke, Kim, Malhotra, Vinay, Devarapalli, Sai K, Koren, Michael, Chandna, Harish, Dodds III, George, Goraya, Tauqir, Bengston, James, Janik, Matthew, Moran, Joseph, Sumner, Andrew, Kobayashi, John, Davis, William, Yazdani, Shahram, Pasquini, John, Thakkar, Maitreya, Vedere, Amarnath, Leimbach, Wayne, Rider, James, Fenton, Sarah, Singh, Narendra, Shah, Anil V, Janosik, Denise, Pepine, Carl, Berman, Brett, Gelormini, Joseph, Daniels, Christopher, Richard, Kerensky, Keating, Friederike, Kondo, Nicholas I, Shetty, Sanjay, Levite, Howard, Waider, Winfried, Takata, Theodore, Abu-Fadel, Mazen, Shah, Vipul, Aggarwal, Rahul, Izzo, Mark, Kumar, Anil, Hattler, Brack, Do, Rose, Link, Chad, Bortnick, Anna, Kinzfogl III, George, Ghitis, Arnold, Larry, John, Teufel, Edward, Kuhlman, Peter, Mclaurin, Brent, Zhang, Wenwu, Thew, Stephen, Abbas, Jalal, White, Matthew, Islam, Othman, Subherwal, Sumeet, Ranadive, Nandkishore, Vakili, Babak, Gring, Christian, Henderson, David, Schuchard, Timothy, Farhat, Naim, Kline, Geoffrey, Mahal, Sharan, Whitaker, Jack, Speirs, Shawn, Andersen, Rolf, Daboul, Nizar, Horwitz, Phillip, Zahr, Firas, Ponce, George, Jafar, Zubair, Mcgarvey, Joseph, Panchal, Vipul, Voyce, Stephen, Blok, Thomas, Sheldon, William, Azizad, Masoud M, Schmalfuss, Carsten, Picone, Mark, Pederson, Robert, Herzog, William, Friedman, Keith, Lindsey, Jason, Nowins, Rosemary, Timothy, Eichenlaub, Leonard, Parilak, Lepor, Norman, El Shahawy, Mahfouz, Weintraub, Howard, Irimpen, Anand, Alonso, Alvaro, May, Wade, Christopher, Daniels, Galski, Thomas, Chu, Alan, Mody, Freny, Ramin, Ebrahimi, Hodes, Zachary, Rossi, Joseph, Rose, Gregory, Fairlamb, James, Lambert, Charles, Raisinghani, Ajit, Abbate, Antonio, Vetrovec, George, King, Marilyn, Carey, Charles, Gerber, Jaime, Younis, Liwa, Park, Hyeun (Tom), Vidovich, Mladen, Knutson, Thomas, Friedman, Dennis, Chaleff, Fred, Loussararian, Arthur, Rozeman, Phillip, Kimmelstiel, Carey, Kuvin, Jeffrey, Silver, Kevin, Foster, Malcolm, Tonnessen, Glen, Espinoza, Andrey, Amlani, Mohamadali, Wali, Andreas, Malozzi, Christopher, Jong, Geert T, Massey, Clara, Wattanakit, Keattiyoat, O'Donnell, Philip J., Singal, Dinesh, Jaffrani, Naseem, Banuru, Sridhar, Fisher, Daniel, Xenakis, Mark, Perlmutter, Neal, Bhagwat, Ravi, Strader, James, Blonder, Ronald, Akyea-Djamson, Ayim, Labroo, Ajay, Lee, Kwan, Marais, H. John, Claxton, Edmund, Weiss, Robert, Kathryn, Rohr, Berk, Martin, Rossi, Peter, Joshi, Parag, Khera, Amit, Khaira, Ajit S, Kumkumian, Greg, Lupovitch, Steven, Purow, Joshua, Welka, Stephen, Hoffman, David, Fischer, Stuart, Soroka, Eugene, Eagerton, Donald, Pancholy, Samir, Ray, Michael, Erenrich, Norman, Farrar, Michael, Pollock, Stewart, French, William J, Diamantis, Steve, Guy, Douglas, Gimple, Lawrence, Neustel, Mark, Schwartz, Steven, Pereira, Edward, Albert, Seals, Spriggs, Douglas, Strain, Janet, Mittal, Suneet, Vo, Anthony, Chane, Majed, Hall, Jason, Vijay, Nampalli, Lotun, Kapildeo, Lester, F. Martin, Nahhas, Ahed, Pope, Theodore, Nager, Paul, Vohra, Rakesh, Sharma, Mukesh, Bashir, Riyaz, Ahmed, Hinan, Berlowitz, Michael, Fishberg, Robert, Barrucco, Robert, Yang, Eric, Radin, Michael, Sporn, Daniel, Stapleton, Dwight, Eisenberg, Steven, Landzberg, Joel, Mcgough, Martin, Turk, Samir, Schwartz, Michael, Sundram, P. Sandy, Jain, Diwakar, Zainea, Mark, Bayron, Carlos, Karlsberg, Ronald, Dohad, Suhail, Lui, Henry, Keen, William, Westerhausen, Donald, Khurana, Sandeep, Agarwal, Himanshu, Birchem, Jessica, Penny, William, Chang, Mark, Murphy, Sherrill, Henry, John, Schifferdecker, Branislav, Gilbert, John M, Chalavarya, Gopal, Eaton, Charles, Schmedtje, John F, Christenson, Stuart, Dotani, Imran, Denham, Douglas, Macdonell, Alexander, Gibson, Paul, Rahman, Aref, Al Joundi, Tammam, Assi, Nizar, Conrad, Gary, Kotha, Purushotham, Love, Michael, Giesler, Gregory, Rubenstein, Howard, Gamil, Dawood, Akright, Laura, Krawczyk, Justine, Cobler, Joanne, Wells, Terry, Welker, James, Foster, Robert, Gilmore, Richard, Anderson, Jay, Jacoby, Douglas, Harris, Bill, Gardner, Geraldine, Dandillaya, Ramprasad, Vora, Kishor, Kostis, John, Hunter, John, Laxson, David, Ball, Eric, Wells, Terry, Vora, Kishor, Ball, Eric, Welker, James, Lopes, Renato, Egydio, Flavia, Kawakami, Anelise, Oliveira, Janaina, Wozniak, Julianna, Matthews, Alexander, Ratky, Caroline, Valiris, Janine, Berdan, Lisa, Hepditch, Anita, Quintero, Kirby, Rorick, Tyrus, Westbrook, Melissa, Pascual, Andrea, Rovito, Carla, Bezault, Madeleine, Drouet, Elodie, Simon, Tabassome, White, Harvey D., Alsweiler, Caroline, Luyten, Anne, Butters, Julie, Griffith, Liddy, Shaw, Michelle, Grunberg, Lena, Islam, Shahidul, Brégeault, Marie-France, Bougon, Nathalie, Faustino, Douglas, Fontecave, Sylvie, Murphy, Judith, Verrier, Melanie, Agnetti, Veronique, Andersen, Dorthe, Badreddine, Emmy, Bekkouche, Mhamed, Bouancheau, Cecile, Brigui, Imane, Brocklehurst, Maddy, Cianciarulo, Joseph, Devaul, Dawn, Domokos, Szilvia, Gache, Cecile, Gobillot, Caroline, Guillou, Severine, Healy, Jan, Heath, Megan, Jaiwal, Gayatri, Javierre, Carine, Labeirie, Julien, Monier, Myriam, Morales, Ulises, Mrabti, Asmaa, Mthombeni, Bicky, Okan, Betim, Smith, Lucile, Sheller, Jennifer, Sopena, Sebastien, Pellan, Valerie, Benbernou, Fadela, Bengrait, Nafissa, Lamoureux, Maud, Kralova, Katarina, Scemama, Michel, Bejuit, Raphael, Coulange, Anthony, Berthou, Christelle, Repincay, Jérôme, Lorenzato, Christelle, Etienne, Alexis, Gouet, Valerie, Lecorps, Guillaume, Loizeau, Virginie, Normand, Mickael, Ourliac, Anne, Rondel, Christelle, Adamo, Antony, Beltran, Pascale, Barraud, Pauline, Dubois-Gache, Helene, Halle, Benjamin, Metwally, Lamia, Mourgues, Maxime, Sotty, Marc, Vincendet, Marion, Cotruta, Raluca, Chengyue, Zhu, Fournie-Lloret, Dominique, Morrello, Christine, Perthuis, Aurelie, Picault, Patrick, Zobouyan, Isabelle, Colhoun, Helen M., Dempsey, Michael A., and McClanahan, Mark A
- Abstract
After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes.
- Published
- 2019
- Full Text
- View/download PDF
19. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease
- Author
-
Bossard, Matthias, Gao, Peggy, Boden, William, Steg, Gabriel, Tanguay, Jean-Francois, Joyner, Cam, Granger, Christopher B, Kastrati, Adnan, Faxon, David, Budaj, Andrzej, Pais, Prem, Di Pasquale, Giuseppe, Valentin, Vicent, Flather, Marcus, Moccetti, Tiziano, Yusuf, Salim, and Mehta, Shamir R
- Abstract
ObjectiveApproximately 10% of patients with myocardial infarction (MI) have no obstructive coronary artery disease. The prognosis and role of intensified antiplatelet therapy in those patients were evaluated.MethodsWe analysed data from the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organisation to Assess Strategies in Ischaemic Symptoms trial randomising patients with ACS referred for early intervention to receive either double-dose (600 mg, day 1; 150 mg, days 2–7; then 75 mg/day) or standard-dose (300 mg, day 1; then 75 mg/day) clopidogrel. Outcomes in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) versus those with obstructive coronary artery disease (CAD) and their relation to standard-dose versus double-dose clopidogrel were evaluated. The primary outcome was cardiovascular (CV) death, MI or stroke at 30 days.ResultsWe included 23 783 patients with MI and 1599 (6.7%) with MINOCA. Patients with MINOCA were younger, presented more frequently with non-ST-segment elevation MI and had fewer comorbidities. All-cause mortality (0.6% vs 2.3%, p=0.005), CV mortality (0.6% vs 2.2%, p=0.006), repeat MI (0.5% vs 2.3%, p=0.001) and major bleeding (0.6% vs 2.4%, p<0.0001) were lower among patients with MINOCA than among those with obstructive CAD. Among patients with MINOCA, 2.1% of patients in the double-dose clopidogrel group and 0.6% in the standard-dose group experienced a primary outcome (HR 3.57, 95% CI 1.31 to 9.76), whereas in those with obstructive CAD, rates were 4.3% and 4.7%, respectively (HR 0.91, 95% CI 0.80 to 1.03; p value for interaction=0.011).ConclusionsPatients with MINOCA are at lower risk of recurrent CV events compared with patients with MI with obstructive CAD. Compared with a standard clopidogrel-based dual antiplatelet therapy (DAPT) regimen, an intensified dosing strategy appears to offer no additional benefit with a signal of possible harm. Further randomised trials evaluating the effects of potent DAPT in patients with MINOCA are warranted.Trial registration numberNCT00335452.
- Published
- 2021
- Full Text
- View/download PDF
20. Assessment of quality of care of patients with ST-segment elevation myocardial infarction
- Author
-
Hudzik, Bartosz, Budaj, Andrzej, Gierlotka, Marek, Witkowski, Adam, Wojakowski, Wojciech, Zdrojewski, Tomasz, Gil, Robert, Legutko, Jacek, Bartuś, Stanisław, Buszman, Paweł, Dudek, Dariusz, and Gąsior, Mariusz
- Abstract
Aims: The 2017 European Society of Cardiology guidelines for the management of ST-elevation myocardial infarction recommended assessing quality of care to establish measurable quality indicators in order to ensure that every ST-elevation myocardial infarction patient receives the best possible care. We investigated the quality indicators of healthcare services in Poland provided to ST-elevation myocardial infarction patients.Methods and results: The Polish Registry of Acute Coronary Syndromes is a nationwide, multicentre, prospective study of acute coronary syndrome patients in Poland. For the purpose of assessing quality indicators, we included 8279 patients from the Polish Registry of Acute Coronary Syndromes hospitalised with ST-elevation myocardial infarction in 2018. Four hundred and eight of 8279 patients (4.9%) arrived at percutaneous coronary intervention centre by self-transport, 4791 (57.9%) arrived at percutaneous coronary intervention centre by direct emergency medical system transport, and 2900 (37.2%) were transferred from non-percutaneous coronary intervention facilities. Whilst 95.1% of ST-elevation myocardial infarction patients arriving in the first 12 h received reperfusion therapy, the rates of timely reperfusion were much lower (ranging from 39.4% to 55.0% for various ST-elevation myocardial infarction pathways). The median left ventricular ejection fraction was 46% and was assessed before discharge in 86.0% of patients. Four hundred and eighty-nine of 8279 patients (5.9%) died during hospital stay. Optimal medical therapy is prescribed in 50–85% of patients depending on various clinical settings. Only one in two ST-elevation myocardial infarction patients is enrolled in a cardiac rehabilitation program at discharge. No patient-reported outcomes were recorded in the Polish Registry of Acute Coronary Syndromes.Conclusions: The results of this study identified areas of healthcare system that require solid improvement. These include direct transport to percutaneous coronary intervention centre, timely reperfusion, guidelines-based medical therapy (in particular in patients with heart failure), referral to cardiac rehabilitation/secondary prevention programs. Also, there is a need for recording quality indicators associated with patient-reported outcomes.
- Published
- 2020
- Full Text
- View/download PDF
21. Comparative Efficacy and Safety of Oral P2Y12Inhibitors in Acute Coronary Syndrome
- Author
-
Navarese, Eliano P., Khan, Safi U., Kołodziejczak, Michalina, Kubica, Jacek, Buccheri, Sergio, Cannon, Christopher P., Gurbel, Paul A., De Servi, Stefano, Budaj, Andrzej, Bartorelli, Antonio, Trabattoni, Daniela, Ohman, E. Magnus, Wallentin, Lars, Roe, Matthew T., and James, Stefan
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2020
- Full Text
- View/download PDF
22. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
- Author
-
Zelniker, Thomas A., Bonaca, Marc P., Furtado, Remo H.M., Mosenzon, Ofri, Kuder, Julia F., Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Budaj, Andrzej, Kiss, Robert G., Padilla, Francisco, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.
- Abstract
Supplemental Digital Content is available in the text.
- Published
- 2020
- Full Text
- View/download PDF
23. Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study
- Author
-
Ramotowski, Bogumił, Gurbel, Paul A., Tantry, Udaya, Bracha, Jan S., Karaźniewicz-Łada, Marta, Lewandowski, Zbigniew, and Budaj, Andrzej
- Published
- 2020
- Full Text
- View/download PDF
24. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin
- Author
-
Vora, Amit N., Alexander, John H., Wojdyla, Daniel M., Aronson, Ronald, Granger, Christopher B., Darius, Harald, Windecker, Stephan, Mehran, Roxana, Averkov, Oleg, Budaj, Andrzej, Kong, David F., Kobalava, Zhanna, Mehta, Rajendra H., Mirza, Zulfiqar, Guimaraes, Patricia Oliveira, Parkhomenko, Alexander, Quadros, Alexandre, Thiele, Holger, Goodman, Shaun G., and Lopes, Renato D.
- Published
- 2019
- Full Text
- View/download PDF
25. Smoking and cardiovascular diseases: paradox greater than expected?
- Author
-
Ramotowski, Bogumił, Gurbel, Paul A., Tantry, Udaya, and Budaj, Andrzej
- Published
- 2019
- Full Text
- View/download PDF
26. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
- Author
-
Held, Claes, White, Harvey D., Stewart, Ralph A.H., Davies, Richard, Sampson, Shani, Chiswell, Karen, Silverstein, Adam, Lopes, Renato D., Heldestad, Ulrika, Budaj, Andrzej, Mahaffey, Kenneth W, Wallentin, Lars, and STABILITY Investigators
- Abstract
Background: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with stable coronary heart disease.Methods: Investigators were instructed to report all potential events. Each reported event was reviewed independently by 2 reviewers according to prespecified processes and prespecified end point definitions. Concordance between reported and adjudicated cardiovascular (CV) events was evaluated, as well as event classification influence on final study results.Results: In total, CEC reviewed 7,096 events: 1,064 deaths (696 CV deaths), 958 myocardial infarctions (MI), 433 strokes, 182 transient ischemic attacks, 2,052 coronary revascularizations, 1,407 hospitalizations for unstable angina, and 967 hospitalizations for heart failure. In total, 71.8% events were confirmed by CEC. Concordance was high (>80%) for cause of death and nonfatal MI and lower for hospitalization for unstable angina (25%) and heart failure (50%). For the primary outcome (composite of CV death, MI, and stroke), investigators reported 2,086 events with 82.5% confirmed by CEC. The STABILITY trial treatment effect of darapladib versus placebo on the primary outcome was consistent using investigator-reported events (hazard ratio 0.96 [95% CI 0.87-1.06]) or adjudicated events (hazard ratio 0.94 [95% CI 0.85-1.03]).Conclusions: The primary outcome results of the STABILITY trial were consistent whether using investigator-reported or CEC-adjudicated events. The proportion of investigator-reported events confirmed by CEC varied by type of event. These results should help improve event identification in clinical trials to optimize ascertainment and adjudication. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
27. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
- Author
-
Ducrocq, Gregory, Schulte, Phillip J., Budaj, Andrzej, Cornel, Jan H., Held, Claes, Himmelmann, Anders, Husted, Steen, Storey, Robert F., Cannon, Christopher P., Becker, Richard C., James, Stefan K., Katus, Hugo A., Lopes, Renato D., Sorbets, Emmanuel, Wallentin, Lars, and Steg, Philippe Gabriel
- Abstract
Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit. We sought to compare the relative effects of ischemic and bleeding events on mortality.
Methods: In the PLATelet inhibition and patient Outcomes (PLATO) trial, we compared spontaneous ischemic events (myocardial infarction or stroke) with spontaneous major bleeding events (PLATO major, Thrombolysis In Myocardial Infarction [TIMI] major, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO] severe) with respect to risk of mortality using time-dependent Cox proportional hazards models. The comparison was performed using ratio of hazard ratios for mortality increase after ischemic vs bleeding events.Results: A total of 822 patients (4.4%) had ≥1 spontaneous ischemic event; 485 patients (2.6%), ≥1 spontaneous PLATO major bleed, 282 (1.5%), ≥1 spontaneous TIMI major bleed; and 207 (1.1%), ≥1 spontaneous severe GUSTO bleed. In patients who had both events, bleeding occurred first in most patients. Regardless of classification, major bleeding events were associated with increased short- and long-term mortality that were not significantly different from the increase associated with spontaneous ischemic events: ratio of hazard ratios (95% CIs) for short- and long-term mortality after spontaneous ischemic vs bleeding events: 1.46 (0.98-2.19) and 0.92 (0.52-1.62) (PLATO major); 1.26 (0.80-1.96) and 1.19 (0.58-2.24) (TIMI major), 0.72 (0.47-1.10) and 0.83 (0.38-1.79) (GUSTO severe) (all P>0.05) CONCLUSIONS: In patients with ACS on dual antiplatelet therapy, spontaneous major bleeding events seem "prognostically equivalent" to spontaneous ischemic complications. This result allows quantitative comparisons between both actual and predicted bleeding and ischemic risks. Our findings help to better define net clinical benefit of antithrombotic treatments and more accurately estimate mortality after ischemic and bleeding events in patients with ACS. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Author
-
Bohula, Erin A, Scirica, Benjamin M, Inzucchi, Silvio E, McGuire, Darren K, Keech, Anthony C, Smith, Steven R, Kanevsky, Estella, Murphy, Sabina A, Leiter, Lawrence A, Dwyer, Jamie P, Corbalan, Ramon, Hamm, Christian, Kaplan, Lee, Nicolau, Jose Carlos, Ophuis, Ton Oude, Ray, Kausik K, Ruda, Mikhail, Spinar, Jindrich, Patel, Tushar, Miao, Wenfeng, Perdomo, Carlos, Francis, Bruce, Dhadda, Shobha, Bonaca, Marc P, Ruff, Christian T, Sabatine, Marc S, Wiviott, Stephen D, Sabatine, Marc S, Wiviott, Stephen D, Scirica, Benjamin M, Inzucchi, Silvio, Keech, Anthony, McGuire, Darren K, Smith, Steven R, Satlin, Andrew, Brown, Conville, Budaj, Andrzej, Corbalan, Ramon, Dwyer, Jamie, Garcia-Castillo, Armando, Gupta, Milan, Hamm, Christian, Kaplan, Lee, Keech, Anthony, Leiter, Lawrence A, Nicolau, Jose Carlos, Oude Ophuis, Ton, Ray, Kauski, Ruda, Mikhail, Scirica, Benjamin M, Spinar, Jindrich, Weissman, Neil, White, Harvey D, Wiviott, Stephen D, Amerena, J, Arstall, M, Colquhoun, D, Jayasinghe, R, Lee, A, Lehman, R, Moses, R, Proietto, J, Purnell, P, Waites, J, Blombery, P, Cross, D, Worthley, M, d'Emden, M, Selvanayagam, J, Oqueli, RE, Whelan, A, Garrahy, P, de Looze, F, Ninio, D, Horowitz, J, William, M, Suranyi, M, Wittert, G, Le May, M, Pandey, AS, Vizel, S, Labonte, R, Beaudry, Y, Fortin, C, Bell, A, Kouz, S, St-Amour, É, Bata, I, St Maurice, F, Chehayeb, R, Constance, C, Wong, G, Hess, A, Liutkus, J, Poirier, P, Teitelbaum, I, Berlingieri, J, Cha, J, Hartleib, M, Heffernan, M, Twum-Barima, D, Pandith, V, Aronson, R, Goldenberg, R, Ajala, B, Jain, A, Ross, S, Bajaj, H, Khandwala, H, Yared, Z, Gupta, N, Bédard, J, Wharton, S, Blouin, F, Savard, D, Shukla, D, Cobos, J, Godoy, G, Perez, L, Pincetti, C, Saavedra Guajardo, V, Varleta, P, Conejeros, C, Lanas, F, Bayram Llamas, E, Cardona Muñoz, E, Garcia, R, Garza Ruiz, J, Llamas Esperon, G, Lopez Rosas, E, Melendez Mier, G, Ramos, G, Hart, H, Scott, D, Ternouth, I, Benatar, J, Elliott, J, Cutfield, R, Manning, P, Williams, M, Ferrier, K, Scott, R, Wilson, S, Leikis, R, Nirmalaraj, BK, Krzyżagórska, E, Miękus, P, Bronisz, M, Mirek-Bryniarska, E, Łanda, K, Stasiewski, A, Żechowicz, T, Zytkiewicz-Jaruga, D, Korecki, J, Ogórek, M, Pawłowicz, L, Piepiorka, M, Skierkowska, J, Stankiewicz, A, Szyprowska, E, Witek, R, Bochenek, A, Kończakowski, P, Wojnowski, Ł, Wujkowski, M, Cymerman, K, Korzeniak, R, Mąder, P, Mikłaszewicz, B, Stachlewski, P, Goch, A, Pomiećko, W, Skórski, M, Romanowski, L, Jusiak, K, Laskowska-Derlaga, E, Bijata-Bronisz, R, Kaźmierczak, J, Goldberg, R, Henderson, D, Korban, E, Rohr, K, Claxton, E, Weiss, R, Angiolillo, D, Boccalandro, F, Chu, K, Thorn, E, Randhawa, P, Singh, N, Bittar, G, Guarnieri, T, Saeed, S, Sharma, S, Shepard, M, French, W, Desai, P, Bernstein, R, Rogers, W, Singal, R, Schneider, R, Shanes, J, Ong, S, Condit, J, Donahoe, S, Brill, D, Einhorn, D, Ebrahimi, R, Labroo, A, Graf, R, Scott, J, Hoekstra, J, Jetty, P, Luckasen, G, O'Donnell, P, Gonte, W, Pomposini, D, Quadrel, M, Koren, M, Schlager, D, Schramm, E, Singal, D, Lupovitch, S, Soni, A, Seigel, P, Roberts, J, Soufer, J, Reza, S, Quinlan, E, Moretto, T, First, B, Khan, M, Chilka, S, Colfer, H, Teklinski, A, Wallace-Wilding, K, Ellison, H, Muse, D, Aronoff, S, Higgins, A, Patel, S, Elinoff, V, Karim, A, Awasty, V, Chuang, R, Roseman, H, Dugano-Daphnis, P, Albert, M, Sheikh, K, Bays, H, Kaster, S, Goldstein, M, Rubino, D, Calatayud, G, Snyder, H, Williams, T, Hershon, K, Hagan, M, Isserman, S, Kahn, B, Anderson, J, Gimness, MP, Raisinghani, A, Christina, M, Raikhel, M, Gillespie, E, Portnay, E, Heiman, M, Qureshi, M, Lee, J, Blonder, R, Cucher, F, Miller, G, Kotlaba, D, Cornett, G, Beavins, J, Augenbraun, C, Reinhardt, S, Bartkowiak, A, Salacata, A, Blevins, T, Benjamin, S, Diener, J, George, W, Barker, B, Richwine, R, Baldari, D, Alfieri, A, Barreto, A, Zhang, L, Shah, R, Hendrix, E, Subramaniyam, V, Hurley, S, Lillestol, M, O'Donoghue, M, Shayani, S, Ryan, E, Call, R, Zemel, L, Chang, A, Kivitz, A, Freyne, B, Bland, V, Shore, K, Mostel, E, Uzoaga, E, Andrawis, N, Gabra, N, Ghitis, A, Sabatino, K, Browder, D, Varma, S, Smith, S, Fink, R, Aycock, GR, Doty, WD, Alfonso, T, Eshaghian, S, Karlsberg, R, Zarich, S, Landau, C, McKenzie, M, Krause, R, Davis, W, Haddad, T, Voyce, S, Alford, C, LeDoux, J, O'Dea, D, McKenzie, M, Park, J, Aroda, V, Getaneh, A, Graham, B, Bhagwat, R, Korn, D, Ruoff, G, Wiseman, A, Lieber, I, Fialkow, J, Gonzalez-Campoy, JM, Bayron, C, Bertolet, B, Lash, J, Gerrish, C, Robertson, D, Rosenfeld, J, Seidner, M, Agaiby, J, Silverfield, J, Sugimoto, D, Lubin, B, Alhaddad, M, Lui, H, Lakin, G, Chokshi, S, Donovan, D, Felten, W, Minton, S, Kimmelstiel, C, Kuvin, J, Still, C, Byars, W, Talano, J, Desai, V, Bradley, AJ, Baker, S, Chane, M, Mercado, A, Baron, S, Harris, B, Mayer, N, Concha, M, Carr, K, Chaykin, L, Willis, J, Clay, A, Fenstad, E, Furda, J, Peterson, P, Chang, M, Aronne, L, Jones, D, Prashad, R, Benson, M, Stegemoller, R, Longshaw, K, Saleh, J, Jennings, W, Detweiler, R, Viswanath, D, Patel, R, Miller, G, Lederman, S, Weinstein, D, Korabathina, R, Singh, V, Rosen, J, Estevez, R, Levin, P, McNeill, R, Kalen, V, Reed, J, Ashley, R, Herman, L, Tsai, Y, Kayne, D, White, A, Hussain, I, Tami, L, Cohen, K, Robinson, J, Sharma, S, Fuchs-Ertman, D, Platt, G, Belardo, L, Reddy, R, Rosendorff, C, Saba, F, Powell, S, Anderson, K, Abidi, M, Rezkalla, S, Paraschos, A, Wilson, J, Moursi, M, Shah, A, Patel, R, Nadar, V, Stonesifer, L, Bialow, M, Cannon, K, Ellison, W, Stedman, M, Brown, J, Harper, W, Lucas, KJ, DiGiovanna, M, Rodbard, H, Biscoveanu, M, Davis, C, Hall, J, Littlefield, R, Gorman, T, Kereiakes, D, Chang, FM, Tatu, H, Cheung, D, Kaine, J, Knutson, T, Logemann, T, Pueblitz, G, Bianco, J, Henson, B, Neustel, M, Gelernt, M, Nelson, W, Moriarty, K, Lefebvre, G, Maw, K, Rink, L, Behn, P, Studdard, H, Argoud, G, O'Connor, T, Krichmar, P, Raad, G, Pereles-Ortiz, J, Sorli, C, Cohen, A, Pettis, K, Cavanaugh, B, Phillips, C, Wahlen, J, Radin, D, Rider, J, Kosinski, E, Leimbach, W, Odhav, A, Hakas, J, Tan, A, Howell, M, Wombolt, D, Fishman, N, Shah, P, Wylie, P, Arauz-Pacheco, C, Cavale, A, George, A, Kroll, R, Krantzler, J, Tahirkheli, N, Jabro, M, Newell, M, Mullen, P, Gencheff, N, Meli, J, Vora, K, Kotek, L, Pyzdrowski, K, Paez, H, Moran, J, Tannenbaum, A, Deck, K, Busch, R, Levinson, L, Azizad, M, Whitaker, J, Fox, B, Huffman, C, Ashraf, M, Diogo, J, Kushner, R, Tallet, J, Channamsetty, V, Suh, D, Atieh, M, Navas, J, Young, V, Shaw, S, Dor, I, Duffy, B, Rubin, P, Lewis, D, Kaye, W, Benton, R, Burbano, J, Hotchkiss, D, Magno, A, Alberton, A, Collins, J, Alvarado, O, Stich, M, Mahal, S, Liu, J, Hong, M, Dy, J, Block, B, Lamantia, J, Pritchard, J, Davis, M, Srivastava, S, Bilazarian, S, Rosario, R, McCartney, M, Blumberg, V, Rajan, R, Martin, E, Wright, S, White, A, Levinson, L, Brinson, C, Johnston, J, Wilson, S, Graves, M, Dominguez, M, McKenzie, W, Abadier, R, Tran, C, Castello, R, Morawski, E, White, J, Morris, F, Perez, A, Trueba, P, Sanchez, M, Andersen, J, Kastelic, R, Khan, J, Rodriguez, H, Izquierdo, W, Matias, A, Essandoh, L, and Ince, C
- Abstract
There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention and remission.
- Published
- 2018
- Full Text
- View/download PDF
29. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial
- Author
-
Bergmark, Brian A., Udell, Jacob A., Morrow, David A., Cannon, Christopher P., Steen, Dylan L., Jarolim, Petr, Budaj, Andrzej, Hamm, Christian, Guo, Jianping, Im, KyungAh, Kuder, Julia F., Braunwald, Eugene, Sabatine, Marc S., and O’Donoghue, Michelle L.
- Abstract
IMPORTANCE: Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with myocardial fibrosis and renin-angiotensin system upregulation, potentially providing prognostic information distinct from standard cardiovascular (CV) biomarkers. OBJECTIVE: To evaluate the association of FGF-23 with recurrent CV events in patients after an acute coronary syndrome (ACS). DESIGN, SETTING, AND PARTICIPANTS: C-terminal FGF-23 was measured in plasma samples using an established enzyme-linked immunosorbent assay system for 4947 patients within 30 days of ACS (median, 14 days) and with 1 additional CV risk factor in the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial of the lipoprotein-associated phospholipase A2 inhibitor darapladib vs placebo performed from December 1, 2009, to April 24, 2014 (median follow-up, 2.5 years). Analyses were adjusted for clinical risk factors, renal function, and established cardiorenal biomarkers. This secondary analysis was performed from September 25, 2014, to October 1, 2017. EXPOSURE: The FGF-23 concentration at baseline. MAIN OUTCOMES AND MEASURES: The primary end point for this post hoc analysis was the composite of CV death or hospitalization for heart failure. RESULTS: In this study, baseline FGF-23 concentrations were available for 4947 patients (median age, 64.0 years; interquartile range, 59.0-71.0 years; 1276 [25.8%] female). Patients with higher FGF-23 concentrations were older and more likely female, with a greater proportion of hypertension, diabetes, and previous myocardial infarction. After multivariable adjustment for baseline clinical characteristics and established biomarkers (high-sensitivity troponin I, brain-type natriuretic peptide, and high-sensitivity C-reactive protein), FGF-23 concentration in the top quartile was independently associated with an increased risk of CV death or heart failure hospitalization (adjusted hazard ratio [HR], 2.35; 95% CI, 1.82-3.02; P < .001) and its individual components. Elevated FGF-23 concentration was also associated with an increased risk of all-cause mortality (adjusted HR, 2.27; 95% CI, 1.73-2.97; P < .001) and CV death, myocardial infarction, or stroke (adjusted HR, 1.42; 95% CI, 1.17-1.71; P < .001). When analyses were stratified by patient sex, the association between FGF-23 and CV risk, including CV death or heart failure, appeared to be attenuated in women (adjusted HR, 1.11; 95% CI, 0.70-1.76; P = .67) compared with men (HR, 3.11; 95% CI, 2.29-4.22; P < .001; P < .001 for interaction). CONCLUSIONS AND RELEVANCE: In patients stabilized after ACS, elevated FGF-23 concentrations may be associated with recurrent major CV events and all-cause mortality, providing information independent of established clinical risk factors and cardiorenal biomarkers. A potential sex difference in these findings deserves further study.
- Published
- 2018
- Full Text
- View/download PDF
30. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- Author
-
Ridker, Paul M, MacFadyen, Jean G, Everett, Brendan M, Libby, Peter, Thuren, Tom, Glynn, Robert J, Ridker, Paul M, MacFadyen, Jean G, Everett, Brendan M, Libby, Peter, Thuren, Tom, Glynn, Robert J, Kastelein, John, Koenig, Wolfgang, Genest, Jacques, Lorenzatti, Alberto, Varigos, John, Siostrzonek, Peter, Sinnaeve, Peter, Fonseca, Francisco, Nicolau, Jose, Gotcheva, Nina, Yong, Huo, Urina-Triana, Miguel, Milicic, Davor, Cifkova, Renata, Vettus, Riina, Anker, Stephan D, Manolis, Athanasios J, Wyss, Fernando, Forster, Tamas, Sigurdsson, Axel, Pais, Prem, Fucili, Alessandro, Ogawa, Hisao, Shimokawa, Hiroaki, Veze, Irina, Petrauskiene, Birute, Salvador, Leon, Cornel, Jan Hein, Klemsdal, Tor Ole, Medina, Felix, Budaj, Andrzej, Vida-Simiti, Luminita, Kobalava, Zhanna, Otasevic, Petar, Pella, Daniel, Lainscak, Mitja, Seung, Ki-Bae, Commerford, Patrick, Dellborg, Mikael, Donath, Marc, Hwang, Juey-Jen, Kultursay, Hakan, Flather, Marcus, Ballantyne, Christie, Bilazarian, Seth, Chang, William, East, Cara, Forgosh, Les, Harris, Barry, and Ligueros, Monica
- Abstract
Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients.
- Published
- 2018
- Full Text
- View/download PDF
31. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- Author
-
Ridker, Paul M, MacFadyen, Jean G, Thuren, Tom, Everett, Brendan M, Libby, Peter, Glynn, Robert J, Ridker, Paul, Lorenzatti, Alberto, Krum, Henry, Varigos, John, Siostrzonek, Peter, Sinnaeve, Peter, Fonseca, Francisco, Nicolau, Jose, Gotcheva, Nina, Genest, Jacques, Yong, Huo, Urina-Triana, Miguel, Milicic, Davor, Cifkova, Renata, Vettus, Riina, Koenig, Wolfgang, Anker, Stephan D, Manolis, Athanasios J, Wyss, Fernando, Forster, Tamas, Sigurdsson, Axel, Pais, Prem, Fucili, Alessandro, Ogawa, Hisao, Shimokawa, Hiroaki, Veze, Irina, Petrauskiene, Birute, Salvador, Leon, Kastelein, John, Cornel, Jan Hein, Klemsdal, Tor Ole, Medina, Felix, Budaj, Andrzej, Vida-Simiti, Luminita, Kobalava, Zhanna, Otasevic, Petar, Pella, Daniel, Lainscak, Mitja, Seung, Ki-Bae, Commerford, Patrick, Dellborg, Mikael, Donath, Marc, Hwang, Juey-Jen, Kultursay, Hakan, Flather, Marcus, Ballantyne, Christie, Bilazarian, Seth, Chang, William, East, Cara, Everett, Brendan, Forgosh, Les, Glynn, Robert, Harris, Barry, Libby, Peter, Ligueros, Monica, Thuren, Tom, Bohula, Erin, Charmarthi, Bindu, Cheng, Susan, Chou, Sherry, Danik, Jacqueline, McMahon, Graham, Maron, Bradley, Ning, MingMing, Olenchock, Benjamin, Pande, Reena, Perlstein, Todd, Pradhan, Aruna, Rost, Natalia, Singhal, Aneesh, Taqueti, Viviany, Wei, Nancy, Burris, Howard, Cioffi, Angela, Dalseg, Anne Marie, Ghosh, Nilanjan, Gralow, Julie, Mayer, Tina, Rugo, Hope, Fowler, Vance, Limaye, Ajit P, Cosgrove, Sara, Levine, Donald, Lopes, Renato, Scott, John, Thuren, Tom, Ligueros, Monica, Hilkert, Robert, Tamesby, Georgia, Mickel, Carolyn, Manning, Brian, Woelcke, Julian, Tan, Monique, Manfreda, Sheryl, Ponce, Tom, Kam, Jane, Saini, Ravinder, Banker, Kehur, Salko, Thomas, Nandy, Panjat, Tawfik, Ronda, O'Neil, Greg, Manne, Shobha, Jirvankar, Pravin, Lal, Shankar, Nema, Deepak, Jose, Jaison, Collins, Rory, Bailey, Kent, Blumenthal, Roger, Colhoun, Helen, Gersh, Bernard, and Glynn, Robert J
- Abstract
Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with canakinumab might alter cancer incidence.
- Published
- 2017
- Full Text
- View/download PDF
32. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial
- Author
-
Bonaca, Marc P., Bhatt, Deepak L., Oude Ophuis, Ton, Steg, P. Gabriel, Storey, Robert, Cohen, Marc, Kuder, Julia, Im, Kyungah, Magnani, Giulia, Budaj, Andrzej, Theroux, Pierre, Hamm, Christian, Špinar, Jindrich, Kiss, Robert G., Dalby, Anthony J., Medina, Felix A., Kontny, Frederic, Aylward, Philip E., Jensen, Eva C., Held, Peter, Braunwald, Eugene, and Sabatine, Marc S.
- Abstract
IMPORTANCE: In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo. OBJECTIVE: To investigate the reasons and timing of discontinuation of treatment with ticagrelor among stable patients prior myocardial infarction. DESIGN, SETTING, AND PARTICIPANTS: In the PEGASUS-TIMI 54 trial, 21 162 stable outpatients with prior myocardial infarction were randomly assigned to 90 mg of ticagrelor twice daily, 60 mg of ticagrelor twice daily, or placebo, with all of the patients receiving a low dose of aspirin. These participants were followed up for a median of 33 months (study start date: October 2010; completion date: December 2014). Discontinuation of treatment was evaluated by treatment arm, cause, and timing. This analysis was initiated in May 2015. MAIN OUTCOME AND MEASURE: Discontinuation of treatment. RESULTS: Over 33 months, 32%, 29%, and 21% of patients receiving 90 mg of ticagrelor, 60 mg of ticagrelor, and placebo, respectively, discontinued treatment (P < .001). Discontinuation of treatment due to an adverse event occurred in 19%, 16%, and 9% of patients, respectively (P < .001). The most frequent adverse events leading to discontinuation of treatment were bleeding (with Kaplan-Meier event rates of 7.8%, 6.2%, and 1.5% of patients, respectively; P < .001) and dyspnea (6.5%, 4.6%, and 0.8% of patients, respectively; P < .001). Eighty-six percent of bleeding events that led to the discontinuation of treatment with ticagrelor were nonmajor, and 86% of adverse events due to dyspnea that led to discontinuation of treatment with ticagrelor were mild or moderate in severity. The discontinuation rates are annualized for patients who received 90 mg of ticagrelor twice daily (hazard ratio [HR], 2.00 [95% CI, 1.84-2.16] for the first year; HR, 1.12 [95% CI, 1.00-1.26] for the second and third years) and patients who received 60 mg of ticagrelor twice daily (HR, 1.59 [95% CI, 1.46-1.73] for the first year; HR, 1.18 [95% CI, 1.06-1.32] for the second and third years) compared with patients who received placebo. CONCLUSIONS AND RELEVANCE: When initiated among stable patients with prior myocardial infarction, discontinuation of treatment with ticagrelor was driven primarily by nonserious adverse events occurring primarily early after randomization. For patients completing 1 year of treatment, the subsequent discontinuation rate was low. These data demonstrate how adverse events considered “nonserious” by traditional trial criteria may have an effect on quality of life and, thus, may precipitate the discontinuation of treatments and underscore the need for patient education and counseling on the timing and nature of adverse effects with the aim of improving adherence when appropriate. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01225562
- Published
- 2016
- Full Text
- View/download PDF
33. Tooth loss is independently associated with poor outcomes in stable coronary heart disease
- Author
-
Vedin, Ola, Hagström, Emil, Budaj, Andrzej, Denchev, Stephan, Harrington, Robert A, Koenig, Wolfgang, Soffer, Joseph, Sritara, Piyamitr, Stebbins, Amanda, Stewart, Ralph HA, Swart, Henk P, Viigimaa, Margus, Vinereanu, Dragos, Wallentin, Lars, White, Harvey D, and Held, Claes
- Abstract
Objective We investigated associations between self-reported tooth loss and cardiovascular outcomes in a global stable coronary heart disease cohort.Methods We examined 15,456 patients from 39 countries with stable coronary heart disease (prior myocardial infarction, prior revascularisation or multivessel coronary heart disease) in the STABILITY trial. At baseline, patients reported number of teeth (26–32 (all), 20–25, 15–19, 1–14 and no teeth) and were followed for 3.7 years. Cox regression models adjusted for cardiovascular risk factors and socioeconomic status, determined associations between tooth loss level (26–32 teeth: lowest level; no teeth: highest level) and cardiovascular outcomes.Results After adjustment, every increase in tooth loss level was associated with an increased risk of the primary outcome, the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke (hazard ratio 1.06; 95% confidence interval 1.02–1.10), cardiovascular death (1.17; 1.10–1.24), all-cause death (1.16; 1.11–1.22) and non-fatal or fatal stroke (1.14; 1.04–1.24), but not with non-fatal or fatal myocardial infarction (0.99; 0.94–1.05). Having no teeth, compared to 26–32 teeth, entailed a significantly higher risk of the primary outcome (1.27 (1.08, 1.49)), cardiovascular death (1.85 (1.45, 2.37), all-cause death (1.81 (1.50, 2.20)) and stroke (1.67 (1.15, 2.39)).Conclusions In this large global cohort of patients with coronary heart disease, self-reported tooth loss predicted adverse cardiovascular outcomes and all-cause death independent of cardiovascular risk factors and socioeconomic status.
- Published
- 2016
- Full Text
- View/download PDF
34. Abstract 10470: Projected Lifetime Benefits of Alirocumab in Patients After Acute Coronary Syndrome
- Author
-
Budaj, Andrzej, Elbez, Yedid, Schwartz, Gregory G, Bhatt, Deepak L, Bittner, Vera A, Chua, Terrance Sing Jin, Diaz, Rafael, Goodman, Shaun G, Harrington, Robert A, Jukema, J Wouter, Kedev, Sasko, Laucevicius, Alexander, MORAIS, JOAO, MURIN, Jan, Parkhomenko, Alexander, Pordy, Robert, Scemama, Michel, Szarek, Michael, White, Harvey D, and Steg, Philippe G
- Abstract
Introduction:In the ODYSSEY OUTCOMES trial, alirocumab improved cardiovascular outcomes and reduced death after acute coronary syndrome (ACS). Median follow-up was 2.8 yrs (range 2-5). The effects of alirocumab on long-term survival are unknown.Objective:To calculate projected life span and potential survival gains with alirocumab vs placebo after ACS using validated nonparametric age-based methods.Methods:In ODYSSEY OUTCOMES (NCT01663402), 18,924 patients with recent ACS and elevated atherogenic lipoproteins despite high-intensity or maximum-tolerated statin therapy were randomized to alirocumab or placebo. All-cause death was a secondary trial outcome. Age-based estimates of projected survival and event-free (all-cause death, nonfatal myocardial infarction, nonfatal ischemic stroke) survival were calculated. In each treatment arm at every year of age, lifespan was estimated from area under the survival curve, to a maximum of 85 yrs. Differences in areas under the survival curves provide an estimate of the benefit of alirocumab on survival.Results:Mean (SD) baseline age was 58.5 (9.3) yrs. Mean survival benefits with alirocumab vs placebo ranged from 0.03 to 1.62 yrs, decreasing with age and becoming neutral at age 80-85 yrs. For example, at age 40, estimated survival was another 37.5 yrs with alirocumab and 35.9 yrs with placebo (difference 1.62 yrs [95% CI, 0.30-2.94]; P=0.016). At age 60, it was 20.5 vs 19.6 yrs (difference 0.88 [95% CI, 0.16-1.61]; P=0.017); at age 75 it was 8.8 vs 8.3 (difference 0.57 [0.09-1.05]; P=0.019); and at age 80, it was 4.5 vs 4.5 years (difference 0.03 [-0.28 to 0.35]; P=0.83). Mean event-free survival benefit similarly ranged from 1.85 to 0.0 yrs.Conclusions:Modeling suggests that long-term treatment with alirocumab may result in a meaningful increase in survival among patients less than 80 yrs of age. This analysis may facilitate shared decision-making with patients. Funding:Sanofi, Regeneron Pharmaceuticals
- Published
- 2022
- Full Text
- View/download PDF
35. Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors
- Author
-
Vedin, Ola, Hagström, Emil, Gallup, Dianne, Neely, Megan, Stewart, Ralph, Koenig, Wolfgang, Budaj, Andrzej, Sritara, Piyamitr, Wallentin, Lars, White, Harvey, and Held, Claes
- Abstract
AimThere are reported links between periodontal disease (PD) and cardiovascular (CV) risk but data are lacking, especially from populations with established coronary heart disease (CHD). This study describes self-reported indicators of PD and associations with CV risk factors in a global stable CHD population.Methods and resultsA total of 15,828 participants in the global STABILITY trial underwent a physical examination, blood sampling, and completed a lifestyle questionnaire. They reported remaining number of teeth (none, 1–14, 15–20, 21–25 or 26–32 (all)) and frequency of gum bleeding (never/rarely, sometimes, often or always). Adjusted linear and logistic regression models assessed associations between tooth loss, gum bleeding, and socioeconomic and CV risk factors.A total of 40.9% of participants had <15 remaining teeth; 16.4% had no teeth; and 25.6% reported gum bleeding with large differences in prevalence among countries, regions and ethnic groups. Less tooth loss was associated with lower levels of glucose, low-density lipoprotein (LDL) cholesterol, systolic blood pressure, waist circumference and hs-CRP; higher estimated glomerular filtration rate; decreased odds for diabetes and smoking, and increased odds for higher education, alcohol consumption and work stress. Gum bleeding was associated with higher LDL cholesterol and systolic blood pressure; decreased odds for smoking, but increased odds for higher education, alcohol consumption and stress.ConclusionSelf-reported indicators of PD were common in this chronic CHD population and were associated with an increasing socioeconomic and CV risk factor burden. However, causality between self-reported PD and CV risk and outcome needs further investigation.
- Published
- 2015
- Full Text
- View/download PDF
36. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes.
- Author
-
Tan, Nigel S, Goodman, Shaun G, Yan, Raymond T, Elbarouni, Basem, Budaj, Andrzej, Fox, Keith A A, Gore, Joel M, Brieger, David, López-Sendón, Jose, Langer, Anatoly, van de Werf, Frans, Steg, Ph Gabriel, and Yan, Andrew T
- Published
- 2013
- Full Text
- View/download PDF
37. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non–ST-segment elevation acute coronary syndromes.
- Author
-
Tan, Nigel S., Goodman, Shaun G., Yan, Raymond T., Elbarouni, Basem, Budaj, Andrzej, Fox, Keith A.A., Gore, Joel M., Brieger, David, López-Sendón, Jose, Langer, Anatoly, van de Werf, Frans, Steg, Ph. Gabriel, and Yan, Andrew T.
- Abstract
Background: ST-segment depression (STD) is predictive of adverse outcomes in non–ST-segment elevation acute coronary syndromes (NSTE-ACS), but there are conflicting data on the incremental prognostic value of T-wave inversions (TWIs) on the admission electrocardiogram. Methods: Admission electrocardiograms of 7,343 patients with NSTE-ACS from the Global Registry of Acute Coronary Events (GRACE) and ACS I registry were independently analyzed at a core laboratory and stratified by TWI and STD status. We performed multivariable analyses to determine the independent prognostic significance of TWI and tested for interaction between TWI and STD for adverse outcomes. Results: Patients with TWI and/or STD had a higher prevalence of cardiovascular risk factors, higher Killip class, and higher GRACE risk scores. Among the 2,708 patients with available angiographic data, rates of 3-vessel or left main disease were similar between patients with TWI and those without TWI/STD. After adjusting for other established prognosticators, TWI did not independently predict in-hospital (adjusted odds ratio 1.03, 95% CI 0.75-1.42, P = .85) or 6-month mortality (adjusted odds ratio 1.02, 95% CI 0.80-1.30, P = .88); STD remained a strong independent predictor. There was no interaction between TWI and STD for these outcomes. No contiguous lead groups or cumulative number of leads with TWI provided independent prognostic information. Conclusions: TWI is associated with other high-risk clinical features but is not an independent predictor of adverse short- and long-term mortality in NSTE-ACS. T-wave inversion does not provide additional prognostication beyond the GRACE risk model, and its concomitant presence does not alter the prognostic value of STD. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
38. Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume: A Substudy of the Multicenter Randomized RIVAL Trial.
- Author
-
Jolly, Sanjit S., Cairns, John, Niemela, Kari, Steg, Philippe Gabriel, Natarajan, Madhu K., Cheema, Asim N., Rao, Sunil V., Cantor, Warren J., Džavík, Vladimír, Budaj, Andrzej, Sheth, Tej, Valentin, Vicent, Fung, Anthony, Widimsky, Petr, Ferrari, Emile, Gao, Peggy, Jedrzejowski, Barbara, and Mehta, Shamir R.
- Subjects
RADIOTHERAPY ,FEMORAL artery ,PERCUTANEOUS coronary intervention ,MYOCARDIAL infarction treatment ,RANDOMIZED controlled trials ,DISEASES - Abstract
Objectives The authors sought to compare the radiation dose between radial and femoral access. Background Small trials have shown an increase in the radiation dose with radial compared with femoral access, but many were performed during the operators' learning curve of radial access. Methods Patients were randomized to radial or femoral access, as a part of the RIVAL (RadIal Vs. femorAL) trial (N = 7,021). Fluoroscopy time was prospectively collected in 5740 patients and radiation dose quantified as air kerma in 1,445 patients and dose-area product (DAP) in 2,255 patients. Results Median fluoroscopy time was higher with radial versus femoral access (9.3 vs. 8.0 min, p < 0.001). Median air kerma was nominally higher with radial versus femoral access (1,046 vs. 930 mGy, respectively, p = 0.051). Median DAP was not different between radial and femoral access (52.8 Gy-cm 2 vs. 51.2 Gy·cm 2 , p = 0.83). When results are stratified according to procedural volume, air kerma was increased only in the lowest tertile of radial volume centers (low 1,425 vs. 1,045 mGy, p = 0.002; middle 987 vs. 958 mGy, p = 0.597; high 652 vs. 621 mGy, p = 0.403, interaction p = 0.026). Multivariable regression showed procedural volume was the greatest independent predictor of lower air kerma dose (ratio of geometric means 0.55; 95% confidence interval 0.49 to 0.61 for highest-volume radial centers). Conclusions Radiation dose as measured by air kerma was nominally higher with radial versus femoral access, but differences were present only in lower-volume centers and operators. High-volume centers have the lowest radiation dose irrespective of which access site approach that they use. (A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Intervention (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy [RIVAL]; NCT01014273 ) [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
39. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for...
- Author
-
Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf S, Lip GY, Hart RG, Flaker, Greg C, Eikelboom, John W, Shestakovska, Olga, Connolly, Stuart J, Kaatz, Scott, Budaj, Andrzej, Husted, Steen, Yusuf, Salim, Lip, Gregory Y H, and Hart, Robert G
- Published
- 2012
- Full Text
- View/download PDF
40. Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin.
- Author
-
Flaker, Greg C., John W. Eikelboom, Olga Shestakovska, Stuart J. Connolly, Scott Kaatz, Budaj, Andrzej, Steen Husted, Salim Yusuf, Gregory Y. H. Lip, and Robert G. Hart
- Published
- 2012
- Full Text
- View/download PDF
41. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients—Results from the PLATelet inhibition and patient Outcomes (PLATO) study.
- Author
-
Åkerblom, Axel, Wallentin, Lars, Siegbahn, Agneta, Becker, Richard C., Budaj, Andrzej, Horrow, Jay, Husted, Steen, Katus, Hugo, Claeys, Marc J., Storey, Robert F., Åsenblad, Nils, and James, Stefan K.
- Abstract
Background: To investigate if ticagrelor treatment and other clinical characteristics were associated with increased cystatin C concentrations and if a deterioration in estimated renal function was associated with worse outcome in patients with acute coronary syndromes (ACS). Methods: Plasma cystatin C concentrations were determined within 24 hours of admission (baseline), at discharge, 1 month, and 6 months in the PLATO trial. The changes over time in relation to randomized treatment were analyzed by analysis of covariance. C-statistics and the relative Integrated Discrimination Improvement of the cystatin C concentrations regarding the primary outcome (cardiovascular death or myocardial infarction) was evaluated by multivariable analysis including background characteristics and biomarkers: N-terminal-pro-B-type natriuretic peptide and Troponin I. Results: Mean cystatin C concentrations in 2133 ticagrelor- and 2162 clopidogrel-treated patients were at baseline (0.86 mg/L and 0.86 mg/L), discharge (1.01 mg/L and 0.98 mg/L) (P < .0005), 1 month (1.00 mg/L and 0.98 mg/L) (P = .12), and 6 months (1.00 mg/L and 0.99 mg/L) (P = .17), respectively. Age, heart failure, and type of ACS were major determinants of the cystatin C concentration. c Statistics and the relative Integrated Discrimination Improvement of the primary outcome for the baseline cystatin C concentration were 0.687 and 5.2%, compared to 0.684 and 4.5% at discharge (n = 4034) and 0.693 and 5.1% at one month (n = 3096), respectively. Conclusions: Mean cystatin C concentrations increased in ACS patients, most importantly determined by age. The initial greater increase in ticagrelor-treated patients was not sustained over time. Risk prediction did not improve with serial measurements of renal markers. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
42. Antiplatelet therapy beyond 2012: role of personalized medicine.
- Author
-
Tantry, Udaya S., Budaj, Andrzej, and Gurbel, Paul A.
- Published
- 2012
- Full Text
- View/download PDF
43. Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non–ST-elevation acute coronary syndromes.
- Author
-
Ali, Sammy, Goodman, Shaun G., Yan, Raymond T., Budaj, Andrzej, Fox, Keith A.A., Gore, Joel M., Brieger, David, López-Sendón, Jose, Langer, Anatoly, van de Werf, Frans, Steg, Ph. Gabriel, and Yan, Andrew T.
- Abstract
Background: Left ventricular hypertrophy (LVH) is frequently associated with ST depression (STD) on the electrocardiogram (ECG), a so-called strain pattern. Although STD is a well-established adverse prognosticator in non–ST-elevation acute coronary syndrome (NSTE-ACS), the relative prognostic importance of LVH and associated STD has not been elucidated. Methods: A total of 7,761 patients with NSTE-ACS in the Global Registry of Acute Coronary Events (GRACE) and ACS-I registries had admission ECGs analyzed at a core laboratory. Left ventricular hypertrophy (determined by Sokolow-Lyon and/or Casale criteria) was observed in 296 (3.8%) patients. We examined the independent association between LVH (determined by the admission ECG) and outcomes in relation to STD. Results: Patients with LVH were older, had more comorbidities and STD, and presented with a higher Killip class. They were less likely to undergo cardiac catheterization (43.1% vs 51.2%, P = .006) and percutaneous coronary intervention (18.3% vs 24.6%, P = .014). Patients with LVH had higher unadjusted mortality at 6 months (10.5% vs 7.1%, P = .038), but similar rates of in-hospital mortality (4.1% vs 3.4%, P = .54) and reinfarction (7.1% vs 7.6%, P = .75). Patients with LVH were more likely to have heart failure in-hospital (21.8% vs 11.8%, P < .001). Among LVH patients, degree of quantitative STD did not predict higher short- or long-term mortality, but was associated with in-hospital heart failure. Multivariable analysis adjusting for other clinical prognosticators of the GRACE risk models revealed that LVH was not a significant independent predictor of in-hospital mortality (adjusted odds ratio = 0.75, 95% CI 0.40-1.41, P = .37) or 6-month mortality (adjusted odds ratio = 0.83, 95% CI 0.52-1.35, P = .44). In contrast, STD remained a strong independent predictor of adverse outcomes. There was no significant interaction between STD and LVH. Conclusions: Across the broad spectrum of NSTE-ACS, LVH is associated with adverse prognostic factors including STD. Electrocardiographic-determined LVH provides no significant additional prognostic utility beyond comprehensive risk assessment using the GRACE risk score. The adverse prognosis associated with LVH in NSTE-ACS may be attributable to other prognosticators such as STD. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
44. In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. The Global Registry of Acute Coronary Events.
- Author
-
López-Sendón, José, Dabbous, Omar H., de Sá, Esteban López, Stiles, Martin, Gore, Joel M., Brieger, David, Van de Werf, Frans, Budaj, Andrzej, Gurfinkel, Enrique P., and Fox, Keith A.A.
- Subjects
THROMBOLYTIC therapy ,PURINERGIC receptors ,HEALTH outcome assessment ,MYOCARDIAL infarction ,HEMORRHAGE risk factors ,MORTALITY ,ANGIOPLASTY ,MULTIVARIATE analysis ,PATIENTS - Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2009
- Full Text
- View/download PDF
45. Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.
- Author
-
Goyal, Abhinav, Mehta, Shamir R., Gerstein, Hertzel C., Díaz, Rafael, Afzal, Rizwan, Xavier, Denis, Zhu, Jun, Pais, Prem, Lisheng, Liu, Kazmi, Khawar A., Zubaid, Mohammad, Piegas, Leopoldo S., Widimsky, Petr, Budaj, Andrzej, Avezum, Alvaro, and Yusuf, Salim
- Abstract
Background: Both a history of diabetes mellitus and elevated inhospital glucose levels predict death after acute myocardial infarction (AMI). However, only diabetes history (and not glucose levels) is routinely considered in AMI risk assessment. Methods: We conducted a post hoc analysis of 2 randomized controlled trials of AMI with ST-segment elevation to compare the prognostic value of inhospital glucose levels with diabetes history in 30,536 subjects. Average inhospital glucose (mean of glucose levels at admission, 6 hours, and 24 hours), diabetes history, and death at 30 days (occurring in 2,808 subjects) were documented. Results: Average glucose predicted 30-day death (OR 1.10 per 1-mmol/L [18-mg/dL] increase, 95% CI 1.09-1.11, P < .0001); this was unchanged after adjusting for diabetes history. In contrast, diabetes history alone predicted 30-day death (OR 1.63, 95% CI 1.48-1.78, P < .0001), but not after adjusting for average glucose (OR 0.98, 95% CI 0.88-1.09, P = .72). The C-indices (areas under the receiver operating characteristic curves) for 30-day death were 0.54 for diabetes history alone, 0.64 for average glucose alone, and 0.64 for glucose plus diabetes. Higher glucose levels predicted death in patients with and without diabetes history, but this relationship was more steep in nondiabetic subjects such that their rate of 30-day death (13.2%) matched that of diabetic patients (13.7%) when average glucose was ≥144 mg/dL (8 mmol/L) (P = .55 after multivariable adjustment). Conclusions: Although diabetes history is routinely considered in the risk stratification of AMI patients, inhospital glucose levels are a much stronger predictor of death and should be incorporated in their risk assessment. Patients with AMI with inhospital glucose ≥144 mg/dL have a very high risk of death regardless of diabetes history. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
46. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk.
- Author
-
Joyner, Campbell D., Peters, Ron J.G., Afzal, Rizwan, Chrolavicius, Susan, Mehta, Shamir R., Fox, Keith A.A., Granger, Christopher B., Franzosi, Maria Grazia, Flather, Marcus, Budaj, Andrzej, Bassand, Jean-Pierre, and Yusuf, Salim
- Abstract
Background: The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS). Methods: We analyzed efficacy and safety according to the GRACE admission risk score. Results: The impact of fondaparinux versus enoxaparin on the primary outcome of death, myocardial infarction, and refractory ischemia at 180 days was similar in the low-, intermediate-, and high-risk groups: 7.0% versus 7.7% (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.75-1.08), 10.2% versus 11.3% (HR 0.89, 95% CI 0.77-1.03), and 20.1% versus 21.1% (HR 0.95, 95% CI 0.85-1.06). Major bleeding rates were higher with increasing GRACE risk scores: 2.2%, 3.2%, and 4.1% in the low, intermediate, and high-risk groups. Six-month mortality was 2.2%, 4.2%, and 12.3% in the 3 groups. The risk of major bleeding was substantially lower with fondaparinux in all groups: 1.6% versus 2.9% (HR 0.55, 95% CI 0.39-0.77), 2.2% versus 4.1% (HR 0.53, 95% CI 0.40-0.70), 2.8% versus 5.5% (HR 0.50, 95% CI 0.38-0.64). Conclusion: The GRACE score predicted both bleeding and mortality in patients with ACS. The efficacy and safety of fondaparinux were consistent in all risk groups supporting its use in a broad range of ACS patients. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
47. Reperfusion in Patients With Renal Dysfunction After Presentation With ST-Segment Elevation or Left Bundle Branch Block: GRACE (Global Registry of Acute Coronary Events).
- Author
-
Medi, Caroline, Montalescot, Gilles, Budaj, Andrzej, Fox, Keith A.A., López-Sendón, José, FitzGerald, Gordon, and Brieger, David B.
- Subjects
CORONARY disease ,MYOCARDIAL infarction ,CONFIDENCE intervals ,REPERFUSION - Abstract
Objectives: We investigated the relative benefit of reperfusion strategies in renal dysfunction and ST-segment elevation/left bundle branch block (STE/LBBB). Background: Few data are available informing the treatment of STE myocardial infarction in the presence of renal dysfunction. Methods: Patients (N = 12,532) from the GRACE (Global Registry of Acute Coronary Events) presenting with STE/LBBB were stratified by renal function and receipt of fibrinolysis, primary percutaneous coronary intervention (PCI), or neither. Results: As renal function declined, hospital mortality increased and reperfusion decreased (both p < 0.001). Compared with no reperfusion, primary PCI was associated with lower hospital mortality in patients with normal renal function (1.9% vs. 3.7%, p = 0.001, adjusted) but no reduction in those with renal dysfunction (14% vs. 15% for glomerular filtration rate [GFR] 30 to 59 ml/min/1.73 m
2 ; 29% vs. 32% for GFR <30 ml/min/1.73 m2 ). Fibrinolysis was not associated with lower hospital mortality for normal (3.1% vs. 3.7%, p = NS) or low renal function (32% vs. 32%, p = NS) and with higher mortality with moderate renal dysfunction (adjusted odds ratio: 1.35, 95% confidence interval: 1.01 to 1.80). Primary PCI was associated with increased hospital bleeding and fibrinolysis with increased stroke in all patients. Among hospital survivors, primary PCI, but not fibrinolysis, was associated with lower mortality for moderate dysfunction. Both reperfusion strategies were associated with higher mortality for severe dysfunction. Conclusions: In STE/LBBB and renal dysfunction, mortality rates are high and reperfusion rates are lower. In moderate renal dysfunction, primary PCI is associated with mortality reduction at 6 months. Outcomes remain poor with severe renal dysfunction, despite receipt of reperfusion therapy. [Copyright &y& Elsevier]- Published
- 2009
- Full Text
- View/download PDF
48. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction study ...
- Author
-
Morrow, David A., Antman, Elliott M., Murphy, Sabina A., Qin, Jie, Ruda, Mikhail, Guneri, Sema, Jacob, Ashok Joseph, Budaj, Andrzej, and Braunwald, Eugene
- Subjects
HEPARIN ,MYOCARDIAL infarction ,CORONARY disease ,HEALTH risk assessment - Abstract
Background: Patients with diabetes mellitus (DM) are at higher risk for complications after ST-elevation myocardial infarction (STEMI) than patients without DM. Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding. Methods: We performed a prospectively planned analysis of efficacy and safety in patients with DM among 20479 patients with STEMI treated with fibrinolysis and randomized to a strategy of enoxaparin (up to 8 days) or unfractionated heparin (UFH) (48 hours) in ExTRACT-TIMI 25. Results: Patients with DM (n = 3060) were older and more likely to be women and to present with heart failure (P < .0001 for each) than those without DM. After adjustment for the TIMI Risk Score, sex, and renal function, patients with DM were at 30% higher risk for death or myocardial infarction (MI) by 30 days (OR
adj 1.29, 95% CI 1.14-1.46). Among patients with DM, the enoxaparin strategy reduced mortality (9.5% vs 11.8%, relative risk [RR] 0.81, 95% CI 0.66-0.99), death/MI (13.6% vs 17.1%, RR 0.80; 95% CI 0.67-0.94), and death/MI/urgent revascularization (16.0% vs 19.7%, RR 0.81, 95% CI 0.70-0.94). The enoxaparin strategy was associated with a trend toward higher major bleeding (2.6% vs 1.6%, RR 1.63, 95% CI 0.99-2.69). Taking efficacy and safety into account, the enoxaparin strategy offered superior net clinical benefit (death/MI/major bleed, 14.8% vs 18.0%, RR 0.83, 95% CI 0.70-0.97) compared with UFH in patients with DM. Conclusions: In a subgroup analysis, a reperfusion strategy including enoxaparin significantly improved outcomes compared with UFH among high-risk STEMI patients with DM undergoing fibrinolysis. [Copyright &y& Elsevier]- Published
- 2007
- Full Text
- View/download PDF
49. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes.
- Author
-
Yan, Andrew T., Yan, Raymond T., Kennelly, Brian M., Anderson, Frederick A., Budaj, Andrzej, López-Sendón, José, Brieger, David, Allegrone, Jeanna, Steg, Gabriel, Goodman, Shaun G., Anderson, Frederick A Jr, López-Sendón, José, and GRACE Investigators
- Subjects
ANGIOPLASTY ,CORONARY disease ,HEART disease diagnosis ,CORONARY arteries - Abstract
Background: Limited data suggest that ST elevation (ST elevation) in aVR is associated with higher mortality and more extensive coronary artery disease in the setting of non-ST elevation acute coronary syndromes (ACS).Methods: In the prospective Global Registry of Acute Coronary Events (GRACE) electrocardiographic substudy, the admission electrocardiograms were analyzed by a blinded core laboratory. We performed multivariable analysis to determine (1) the independent prognostic significance of ST elevation in aVR and (2) its association with significant (> or = 50% stenosis) left main or 3-vessel disease (LM/3-vd).Results: Among 5064 patients with non-ST elevation ACS, 4696 had no ST elevation in aVR, 292 (5.8%) had minor (0.5-1 mm) ST elevation in aVR, and 76 (1.5%) had major (>1 mm) ST elevation in aVR; their in-hospital mortality rates were 4.2%, 6.2%, and 7.9%, respectively (P for trend =.03). At 6 months follow-up, the cumulative mortality rates were 7.6%, 12.7%, and 18.3%, respectively (log-rank P for trend <.001). However, minor and major ST elevation in aVR were not independent predictors of in-hospital or 6-month death after adjusting for other validated prognosticators in the GRACE risk model. Of the 2416 patients without prior coronary bypass surgery who underwent cardiac catheterization, the prevalence of LM/3-vd was 26.1%, 36.2%, and 55.9% for the groups with no, minor, and major ST elevation in aVR, respectively (P for trend <.001). After adjusting for other clinical characteristics, major ST elevation in aVR remained an independent predictor of LM/3-vd (adjusted odds ratio, 2.68; 95% confidence interval, 1.29-5.58; P = .008).Conclusion: ST elevation in aVR is less prevalent than reported in previous smaller studies. Although it is associated with higher unadjusted in-hospital and 6-month mortality, it does not provide incremental prognostic value beyond comprehensive risk stratification using the validated GRACE risk model. However, ST elevation greater than 1 mm in aVR may be useful in the early identification of LM/3-vd in ACS patients with ST depression. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
50. Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification.
- Author
-
Oliveira, Gustavo B.F., Avezum, Alvaro, Anderson, Frederick A., Budaj, Andrzej, Dabbous, Omar H., Goodman, Shaun G., Steg, Philippe Gabriel, Goldberg, Robert J., Brieger, David, Fox, Keith A.A., Gore, Joel M., and Granger, Christopher B.
- Subjects
CATHETERIZATION ,HEALTH risk assessment ,CARDIAC surgery ,RISK management in business - Abstract
Background: Current guidelines advise the use of risk stratification to determine which patients should receive more aggressive antithrombotic and invasive therapies. Our objective was to evaluate the relationship between risk stratification and therapeutic decision making in patients with non–ST-segment elevation acute coronary syndromes. Methods: We analyzed data from 15026 patients with acute coronary syndrome who were enrolled into the GRACE registry between 1999 and 2003. We assessed the evidence-based use of antithrombotic therapy and early invasive strategy according to risk profile defined by baseline troponin elevation, presenting ST-segment depression, and GRACE risk score. Patients with possible contraindications were removed to define the use of therapies specifically among clearly eligible patients. Results: Patients with elevated troponin were more likely to receive enoxaparin (60% vs 50.4%, respectively), GP IIb/IIIa inhibitors (32.8% vs 17.6%), and to undergo catheterization (66% vs 54%) and percutaneous coronary intervention (37.4% vs 25.6%; all P < .0001). Patients with ST depression received modestly more enoxaparin and GP IIb/IIIa than those without ST depression, but not more catheterization (P = .8) or percutaneous coronary intervention (P = .09). Highest risk patients were somewhat less likely to receive enoxaparin (P < .0001) and cardiac catheterization (P = .0002) according to GRACE risk deciles. Conclusions: In spite of current guidelines recommending the use of selected therapies in high-risk patients, there is no clear correlation of use of effective therapies with overall risk profile even among eligible patients. Thus, there is substantial opportunity to improve use of effective therapies, especially in high-risk populations. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.